

# APSARD 2019 ANNUAL MEETING

*ADHD: Exploring the Boundaries*

## PROGRAM BOOK

JANUARY 18-20, 2019

WASHINGTON MARRIOTT

WARDMAN PARK

WASHINGTON, D.C.

JOINTLY SPONSORED BY:

**APSARD**

The American Professional Society  
of ADHD and Related Disorders





Dear APSARD Colleagues:

It is my pleasure to welcome you to the 2019 Meeting of the American Professional Society of ADHD and Related Disorders! APSARD is the premier, multidisciplinary organization devoted to the advancement of both the science and clinical practices benefitting individuals with ADHD throughout the lifespan. This year's program is enriched with state-of-the-art plenaries, symposia addressing key issues, posters, and networking opportunities with prominent investigators, clinicians, and colleagues from around the globe who all come to APSARD.

Despite increased awareness of ADHD in all age groups, huge educational gaps remain among primary and specialty care providers, and there is limited access to evidence-based treatments, especially in adults. We need your help in broadening the reach of APSARD and achieving our scientific and educational goals.

Please introduce yourself to any board member or officer if you have suggestions or feedback and ask about volunteering for APSARD committees. We also hope you will participate in our educational activities throughout the year, refer colleagues for membership, and become more involved through the year.

I know you will enjoy the meeting and interacting with your APSARD colleagues.

With warm regards,

Joseph Biederman, M.D.  
APSARD President



## **Welcome to the APSARD Annual Meeting**

On behalf of the APSARD Annual Meeting Program Committee, we are delighted to welcome you to the 2019 APSARD Annual Meeting.

The conference features nationally and internationally renowned faculty who present recent research findings relevant to clinical practice. If you are new to APSARD and/or the annual meeting, I would like to highlight that APSARD takes great pride in recruiting faculty from the US and abroad who are pre-eminent in the ADHD field, and offering presentations that represent cutting edge science in a manner that is accessible to and informative for clinicians and clinician-researchers. A summary of the schedule is presented below. To me, all sessions are highlights!

- Friday, January 18
  - Opening Plenary, *New Perspectives on Impulsive Choice in ADHD: Refining the Phenotype and Augmenting Therapeutic Options*
  - Poster Presentations and Welcome Reception
- Saturday, January 19
  - Breakfast for Travel Awardees
  - President's Summary
  - Plenary Session: *The Relevance of Biological and Environmental Risk Factors in the ADHD*
  - Lifetime Achievement Award Plenary: Martha Denckla, M.D.
  - Poster Presentations with Lunch – Including a Data Blitz Session
  - Symposium Sessions on *Risk Factors and Treatment of ADHD and Substance Use Disorders: From Science to Clinical Practice* and *Benefits and Challenges of Psychosocial Treatment in ADHD*
  - Meet the Experts Sessions (Psychosocial and Pharmacotherapy)
  - Reception
- Sunday, January 20
  - APSARD Business Meeting and Awards Presentation
  - Plenary Sessions, *Genetics of ADHD and Implications for Educating Patients and Managing the Disorder* and *Relevance of Imaging in Understanding ADHD*
  - Lunch Discussion Groups on *Imaging and EEG: What Clinicians Should Know* and *Adult ADHD: Young Adults through Geriatric*
  - Symposia Sessions: *Bipolar Disorder as it Relates to ADHD* and *Seizures, Tics, and OCD in ADHD: Impact on Management*

### **Organization**

- The meeting is sponsored by the American Society for ADHD and Related Disorders (APSARD).
  - The Program Committee develops program content and invites speakers, evaluates submitted proposals.
- Parthenon Management Group organizes the APSARD Annual Meeting.

The APSARD Annual Meeting is an opportunity for education and networking. We welcome your suggestions to make the event even better. Seek us out during the meeting or provide your views by completing the evaluation form.

Most importantly, please join us and become a member if you are not already!

Best Regards,

Steven Pliszka, M.D.  
UT Health Science Center at San Antonio

# Get Connected...

Download the mobile app for the 2019 APSARD Annual Meeting

Search “APSARD2019” in the App Store for iPhones  
And Google Play Store for Androids today!

**The mobile app is a tool that will allow you to browse the Annual Meeting Schedule, view abstracts, and plan your agenda for the meeting.**

- Tap the Program icon to search the schedule by date and time. Tapping a session will show additional information such as speakers and abstracts.
- Use the Attendees icon to view the APSARD attendee list.
- Tap the Info icon to view helpful documents such as a Dining Guide, maps of the meeting space and the neighborhood around the hotel, and a list of presenter disclosures.
- The Facebook and Twitter icons will connect you directly to APSARD social media.
- Logging into the app will allow you to “pin” sessions to your schedule that can be uploaded to your phone calendar.



**Don't forget to follow us on social media!**



## **APSARD 2019 Wi-Fi**

Network: Marriott CONFERENCE

Password: apsard2019

**TABLE OF CONTENTS**

Meeting Space Maps ..... 5

Award Winners and Featured Speakers ..... 7

Acknowledgements..... 19

Meeting Announcements ..... 21

Friday, January 18, 2019..... 27

Saturday, January 19, 2019..... 31

Sunday, January 20, 2019..... 41

Posters ..... 51

Author Index ..... 65


Notes..... 69

**Disclosures for all APSARD presenters can be  
viewed at [www.APSARD.org](http://www.APSARD.org)**




## MEETING SPACE MAPS

## MEZZANINE LEVEL



## EXHIBITION LEVEL



## NOTES

[illegible]



## AWARD WINNERS

### Lifetime Achievement Award



**Martha Bridge Denckla, M.D.**

Kennedy Krieger Institute / Neurology at Johns Hopkins University School of Medicine

Dr. Denckla graduated *summa cum laude* from Bryn Mawr College and went on to graduate *cum laude* from Harvard Medical School in 1962, after which she trained with Dr. Norman Geschwind in behavioral neurology. Dr. Denckla served residencies at Beth Israel Hospital and Veterans Administration Hospital, both in

Boston, as well as Georgetown University Medical Center in Washington DC. After positions in neurology at the College of Physicians and Surgeons in New York, she was on the faculty of Harvard Medical School and served as the director of the Learning Disabilities Clinic at Boston Children's Hospital. After moving to Maryland in 1979, Dr. Denckla took a position at NINDS/NIH to serve as Chief of the Section on Autism and Related Disorders. She came to the Kennedy Krieger Institute and Johns Hopkins University in 1987 and has since served as Director of the Developmental Cognitive Neurology Department at the Kennedy Krieger.

Since 2008, Dr. Denckla has devoted the time and effort previously spent in the role of Research Principal Investigator to the transfer of information on the developing brain and its milder learning differences to educators, including five years as Adjunct Professor in the Johns Hopkins University School of Education. In this role, she taught fellows in the Kennedy Krieger Institute Center for Innovation and Leadership in Special Education, and consulted to the Fairfax County, Virginia Public Schools on dyslexia.

Dr. Denckla is a past president of both the International Neuropsychology Society and the Behavioral Neurology Society. Dr. Denckla has been awarded the Lucy G. Moses Prize in Clinical Neurology at Columbia University, the Norman Geschwind Memorial Lectureship at Orton Society, the Rita G. Rudel Memorial Lectureship at Columbia University, the Herbert Birch Memorial Lectureship at the International Neuropsychology Society, the Soriano Guest Lectureship of the American Neurological Association and the Bernard Sachs Lectureship of Child Neurological Society. She was the American Academy of Mental Retardation Research Center awardee and in 2013 won the career award given on the occasion of the 50th anniversary of the Learning Disabilities Association (LDA). In 2015, Dr. Denckla was recognized by Johns Hopkins University as its first woman Professor of Neurology and fifteenth woman to be full Professor there in the history of the Medical School.

# AWARD WINNERS

## Recipient of the Best Paper in the Journal of Attention Disorders Award

*Adult Outcome of ADHD: An Overview of Results From the MGH Longitudinal Family Studies of Pediatrally and Psychiatrically Referred Youth With and Without ADHD of Both Sexes*

Mai Uchida, Thomas J. Spencer, Stephen V. Faraone, and Joseph Biederman



**Mai Uchida, M.D.**  
Massachusetts General Hospital

Dr. Mai Uchida is Assistant Professor of Psychiatry at Harvard Medical School and, Staff Psychiatrist in the Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD. Dr. Uchida is a dedicated clinician to both children and adults. She also conducts research to better understand and advance care for various psychiatric disorders.

Her research career focus has been on the characteristics, longitudinal course and treatment of unipolar and bipolar pediatric depression. In collaboration with Drs. John and Susan Gabrieli at MIT, she has published on the fMRI-based biomarkers of the risk for development of major depression and received the First Prize Department of Psychiatry Award of MGH as well as the Dupont Warren Fellowship and Livingston Award for her works on this topic. She has done clinical and neuroimaging-based investigation of emotional dysregulation and has received the Louis V Gertsner Award for this work. She has multiple publications on evaluations of screening tools, longitudinal follow ups and systematic reviews on pediatric depression.

Another area of Dr. Uchida’s expertise is in adult and pediatric Attention-Deficit/Hyperactivity Disorder (ADHD). She is also the recipient of the Elaine Schlosser Lewis Award from the American Academy of Child and Adolescent Psychiatry to investigate the utilization of health technology in improving management of ADHD.

In addition, Dr. Uchida is a committed advocate for mental health. She has articulated her thoughts in a number of international publications, including the International Herald Tribune and Asahi Shimbun, on topics ranging from suicide prevention and informed consent to the experience of being a Japanese female physician in America.

## **AWARD WINNERS**

### **Travel Awardees**

**Anne Arnett, Ph.D.**  
University of Washington

**Agnieszka Mlodnicka, Ph.D.**  
University of California Davis

**Laura Eddy, Ph.D.**  
University of North Carolina  
Greensboro

**Michael Tate, M.A.**  
City College of New York

**Weam Fageera, M.Sc.**  
McGill University

**Lea Taylor, B.A.**  
Syracuse University

**Jonathan Hess, Ph.D.**  
SUNY Upstate Medical University

**Kelsey Wiggs, B.A., B.S.**  
Indiana University

### **Developmental-Behavioral Pediatrics APSARD Award**

**Nicholas Fogleman, M.S.**  
Cincinnati Children's Hospital Medical Center

## FEATURED SPEAKERS



**Friday, January 18, 2019 from 5:30 p.m. – 7:30 p.m.**  
***Why Are We (Not) Waiting? New Perspectives on the Neuroscience of Impulsive Choice in ADHD***  
**Thurgood Marshall Ballroom**

**Edmund Sonuga-Barke, M.Sc., Ph.D., F.Med.Sci.**  
King's College London

Edmund Sonuga-Barke is currently Professor of Developmental Psychology, Psychiatry and Neuroscience working in the Department of Child and Adolescent Psychiatry at the Institute of Psychology, Psychiatry and Neuroscience, King's College London. He also holds Visiting Chairs at Ghent University, Aarhus University and the University of Sussex. He is Editor in Chief of the Journal of Child Psychology and Psychiatry.

His work integrates Developmental Psychopathology and Neuroscience perspectives to employing basic developmental science approaches to study the pathogenesis of neuro-developmental and mental health conditions; their underlying genetic and environmental risks, mediating brain mechanisms and developmental outcomes. He has a particular interest in ADHD and related disorders.

In 2016, Prof Sonuga-Barke was elected a Fellow of the Academy of Medical Sciences.

## FEATURED SPEAKERS



**Friday, January 18, 2019 from 5:30 p.m. – 7:30 p.m.**  
***Pills, Skills and Behaviours: Exploring the***  
***Psychopharmacology of Impulsivity***  
**Thurgood Marshall Ballroom**

**David Coghill, M.D.**  
University of Melbourne

Dave Coghill took up post as Chair of Developmental Mental Health at the University of Melbourne in February 2016. Before this he was professor of child and adolescent psychiatry at the University of Dundee. He is a child and adolescent psychiatrist by training. His research focuses on developing a better understanding of the pathophysiology of ADHD, conduct disorder and depression using a range of approaches including neuropsychopharmacology, neuroimaging and genetics and developing and personalizing approaches to the treatment of child and adolescent mental health problems through the development of biomarkers, neurocognitive phenotypes, clinical trials, pharmacoepidemiology and patient reported outcomes. He has maintained a strong clinical presence and has worked hard to develop clinical pathways that facilitate the rapid transfer of research evidence into routine clinical practice. In addition to his academic role at the University of Melbourne where he is Deputy Head of the Department of Pediatrics, he is part of the neurodevelopmental disorders team at The Royal Children's Hospital, Melbourne.

## FEATURED SPEAKERS



**Saturday, January 19, 2019 from 9:00 a.m. – 11:00 a.m.**  
***Catecholamine Regulation of Prefrontal Cortex:***  
***Relevance to Etiology and Treatment of ADHD***  
**Thurgood Marshall Ballroom**

**Amy Arnsten, Ph.D.**

Yale Medical School

Dr. Arnsten is an expert on the molecular regulation of the prefrontal cortical circuits most impacted by ADHD. Arnsten received her undergraduate degree in Neuroscience from Brown University in 1976, and her Ph.D. in Neuroscience from UCSD in 1981. She did a brief post-doctoral fellowship with Susan Iversen at Cambridge University, UK before becoming a post-doctoral fellow with Patricia Goldman-Rakic at Yale, studying neuromodulatory influences on the primate prefrontal association cortex. Arnsten is currently Professor of Neuroscience at Yale Medical School, with joint appointments in Psychiatry, Psychology and the Yale Child Study Center. Arnsten is the recipient of the Goldman-Rakic Prize for Outstanding Research in Cognitive Neuroscience, and a member of the National Academy of Medicine. Arnsten is one of the few basic researchers whose work in animals has successfully translated to human therapies: guanfacine (Intuniv™) for the treatment of ADHD and related prefrontal cognitive disorders, and prazosin for the treatment of PTSD.

## FEATURED SPEAKERS



**Saturday, January 19, 2019 from 9:00 a.m. – 11:00 a.m.**  
***The Relevance of Biological and Environmental Risk Factors in the ADHD***  
**Thurgood Marshall Ballroom**

**Joel Nigg, Ph.D.**  
Oregon Health & Science University

Joel Nigg, Ph.D., is a Professor of Psychiatry and Behavioral Neuroscience and Director of the Division of Psychology at Oregon Health & Science University in Portland, Oregon. He obtained an AB degree from Harvard, MSW from The University of Michigan, and Ph.D. from UC Berkeley. He is a Fellow in the Society for Psychological Science, has served on numerous journal editorial boards, and his work has been continuously funded by NIMH for over 20 years. His team has published some 200 papers related to ADHD; the work is most known for contributions related to neuropsychology, cognition, and temperament as well as work on heterogeneity, in relation to ADHD.

## FEATURED SPEAKERS



**Saturday, January 19, 2019 from 9:00 a.m. – 11:00 a.m.**  
***Comorbidity of Attention Deficit Disorder and Physical Conditions: Explanations and Impact***  
Thurgood Marshall Ballroom

**Kathleen Merikangas, Ph.D.**  
National Institutes of Health

Dr. Merikangas is Senior Investigator and Chief of the Genetic Epidemiology Branch in the Intramural Research Program at the National Institute of Mental Health (NIMH) with expertise in epidemiology, genetics and clinical psychiatry. Her research involves large scale community studies of patterns of sleep, physical activity, and both mental and physical conditions in of adults and youth; multigenerational family studies designed to identify the core features and biomarkers of bipolar spectrum disorders. Their work on the application of mobile technologies to examine patterns of motor activity, mood and sleep in mood disorders has led to their coordination of a collaborative network examining motor activity and health, the Motor Activity Research Consortium on Health (mMARCH) in adults and youth. With several other labs in the Intramural Program at NIMH, she is leading a cross-species program of research on genetic and environmental influences on motor activity and related homeostatic systems.



## FEATURED SPEAKERS



**Sunday, January 20, 2019 from 9:00 a.m. – 10:30 a.m.**  
***Genetics of ADHD and Implications for***  
***Educating Patients and Managing the Disorder***  
**Thurgood Marshall Ballroom**

**Stephen Faraone, Ph.D.**  
SUNY Upstate Medical University

Stephen Faraone, Ph.D., is a Distinguished Professor in the Departments of Psychiatry and Neuroscience & Physiology at SUNY Upstate Medical University. He is also Senior Scientific Advisor to the Research Program Pediatric Psychopharmacology at the Massachusetts General Hospital and a lecturer at Harvard Medical School. Prof. Faraone founded the ADHD Subgroup of the Psychiatric Genomics Consortium (PGC) and was a founding member of the PGC Coordinating Committee. He is also Editor of Neuropsychiatric Genetics. Prof. Faraone studies the nature and causes of mental disorders in childhood and has made contributions to research in psychiatric genetics, psychopharmacology, diagnostic issues and methodology. An author on over 800 journal articles, editorials, chapters and books, he was the eighth highest producer of High Impact Papers in Psychiatry from 1990 to 1999 as determined by the Institute for Scientific Information (ISI, Science, 2000, Vol 288, pg. 959). In 2005, ISI determined him to be the second highest cited author in the area of Attention Deficit Hyperactivity Disorder (<http://www.esi-topics.com/add/interviews/StephenFaraone.html>) and in 2013 he was the third most highly cited researcher in psychiatry and psychology (<http://academic.research.microsoft.com/>). From 2014 to 2018 he has been listed as a highly cited researcher by Thomson Reuters/Clarivate Analytics. His lifetime H-Index as of Feb 2018 was 188.

## FEATURED SPEAKERS



**Sunday, January 20, 2019 from 9:00 a.m. – 10:30 a.m.**  
***Genetics of ADHD and Implications for  
Educating Patients and Managing the Disorder***  
**Thurgood Marshall Ballroom**

**Jim Kennedy, M.D., FRCPC, FRSC**

Centre for Addiction and Mental Health,  
University of Toronto

Dr. Kennedy has training in three major areas: neuroscience, clinical psychiatry, and molecular genetics. His main research interest over the past 25 years has been the identification of susceptibility genes for psychiatric disorders. This has involved extensive hypothesis-based investigations of genetic variation in neurobiological systems known to be involved in psychiatric disorders and addictions. Discoveries from his Neurogenetics laboratory include: 1) the role of the DRD4 gene in ADHD, one of the most consistently replicated findings in all of behavioral genetics; 2) the genetic mapping, and role of the 5HT1B gene in OCD and ADHD; 3) the discovery of the role of the DRD3 gene in predicting Tardive Dyskinesia (issued US patent); 4) prediction of the serious side effect of antidepressant-induced mania (issued US patent); and 5) the role of glutamate system genes (SLC1A1 and GRIN2B) in Obsessive Compulsive Disorder. He has one of the most comprehensive collections of DNAs (N = 34,000) for any one institution in the world in terms of range of psychiatric disorders (N=18) and sub-phenotypes (N=50+). He is leading an ongoing psychiatric pharmacogenetics research program (N=11,200 currently), and research clinical trials (N=600) involving patients with schizophrenia and depression. Thus, he is well-positioned to examine any psychiatric genetic finding to determine its role, if any, across the entire spectrum of mental illnesses and addictions. He has trained over 25 graduate students and 55 research fellows, some of whom are now Full Professors in North America and Japan. Dr. Kennedy is Head of the Molecular Brain Science Department at CAMH that oversees research in genetics, epigenetics, molecular biology, molecular pharmacology, stem cell methods, and molecular bioinformatics. In addition to genetics of most major psychiatric disorders Dr. Kennedy leads the Tanenbaum Centre for pharmacogenetics and the large IMPACT study, including over 500 children and youth, that is developing new genetic tests to predict medication response and side effects.

## FEATURED SPEAKERS



**Sunday, January 20, 2019 from 11:00 a.m. – 12:30 p.m.**  
***Relevance of Imaging in Understanding ADHD***  
**Thurgood Marshall Ballroom**

**Adriana Di Martino, M.D.**  
The Child Mind Institute

Adriana Di Martino, M.D., is an internationally recognized autism researcher and the founding research director for the Autism Center at the Child Mind Institute.

Dr. Di Martino has a long-standing research interest in autism spectrum disorder and how to best understand its neurobiology using brain imaging and a range of other clinical and cognitive approaches. Her study places a particular emphasis on detecting autism-related differences in brain connectivity that emerge in early childhood, with the goal of identifying objective biological markers that can one day be used to improve early intervention efforts and the selection of treatments.

In order to accelerate the pace of autism research, Dr. Di Martino established and directs the Autism Brain Imaging Data Exchange (ABIDE), which aggregates and shares functional and structural brain imaging data from laboratories around the world. The datasets made available to the scientific community by ABIDE have attracted a broad range of researchers to the study of autism, with expertise ranging from neuroscience and psychology to statistics, mathematics and engineering. New insights are emerging through the studies of ABIDE at a rate of more than a publication per month.

Dr. Di Martino is also a leader in efforts to recognize and understand overlaps in the neural bases of other neurodevelopmental conditions that commonly co-occur with autism, such as attention-deficit hyperactivity disorder. Insights from this work are helping to provide a better understanding of differences in the clinical presentation of autism among individuals, as well as variations in the responses of treatment.

Dr. Di Martino is one of our nation's most prolific researchers in the neuroimaging of autism, with publications in the most scientifically respected journals in the field of psychiatry, including the JAMA-Psychiatry, American Journal of Psychiatry, Biological Psychiatry and Molecular Psychiatry. She has also received honors and funding support from the National Institute of Mental Health (NIMH) and the Simons Foundation and has been invited to lecture at multiple national and international scientific conferences.

## FEATURED SPEAKERS



**Sunday, January 20, 2019 from 11:00 a.m. – 12:30 p.m.**  
***Relevance of Imaging in Understanding ADHD***  
**Thurgood Marshall Ballroom**

**Philip Shaw, Ph.D.**

National Human Genome Research Institute

Philip Shaw is an Earl Stadtman Investigator at the Neurobehavioral Clinical Research Section of the National Human Genome Research Institute in Bethesda, United States. His main interest is in the genetic and environmental factors that influence the development of brain and behavior. A focus of his work is one the most common neuropsychiatric disorders of childhood, attention deficit hyperactivity disorder. He has degrees in experimental psychology and medicine from Oxford University, and a Ph.D. in psychological medicine from the Institute of Psychiatry in London. He completed residencies in internal medicine and psychiatry in England and is a member of both the Royal College of Physicians and the Royal College of Psychiatry.

# ACKNOWLEDGEMENTS

## Program Committee Members

Steven Pliszka, M.D.  
*Program Committee Chair*  
University of Texas San Antonio

Jeffrey Newcorn, M.D.  
Icahn School of Medicine  
at Mount Sinai

Joseph Biederman, M.D.  
Massachusetts General Hospital

Scott Kollins, Ph.D.  
Duke University

Frances Levin, M.D.  
Columbia University Medical Center

Jonathan Posner, M.D.  
Columbia University

Luis Rohde, M.D.  
Federal University of  
Rio Grande Do Sul

Russell Schachar, M.D.  
University of Toronto

## APSARD Officers and Board

Joseph Biederman, M.D.  
*President*  
Massachusetts General Hospital

Jeffrey Newcorn, M.D.  
*President Elect*  
Icahn School of Medicine  
at Mount Sinai

Mark Stein, Ph.D., ABPP  
*Past President*  
Seattle Children's Hospital

Martin Katzman, B.Sc., FRCP(C), M.D.  
*Treasurer*  
START Clinic for Mood  
and Anxiety Disorders

Karen Seymour, Ph.D.  
*Secretary*  
Johns Hopkins University  
School of Medicine

Lenard Adler, M.D.  
NYU School of Medicine

Lawrence Brown, M.D.  
Children's Hospital of Philadelphia

Thomas Brown, Ph.D.  
Keck School of Medicine of  
University of Southern California

Betsy Busch, M.D., FAAP  
Tufts University School of Medicine

Ann Childress, M.D.  
Center for Psychiatry and  
Behavioral Medicine, Inc.

Tanya Froehlich, M.D.  
Cincinnati Children's  
Hospital Medical Center

# ACKNOWLEDGEMENTS

## APSARD Officers and Board (continued)

David Goodman, M.D.  
Johns Hopkins School of Medicine

Andrew Nierenberg, M.D.  
Massachusetts General Hospital

John Heiligenstein, M.D.  
Pharmaceutical Industry

Anthony Rostain, M.D., MA  
University of Pennsylvania

Beth Krone, Ph.D.  
Icahn School of Medicine at Mount  
Sinai

Mary Solanto, Ph.D.  
New York University School of  
Medicine

Greg Mattingly, M.D.  
Washington University School of  
Medicine

Craig Surman, M.D.  
Massachusetts General Hospital

Keith McBurnett, Ph.D.  
University of California, San  
Francisco

Roberta Waite, Ed.D  
Drexel University

Brooke Molina, Ph.D.  
University of Pittsburgh

Margaret Weiss, M.D., Ph.D.  
University of British Columbia  
Children and Women's Health  
Centre

# MEETING ANNOUNCEMENTS

## Meeting Services

### **Registration**

Thurgood Marshall Foyer on the Mezzanine Level

Friday, January 18 2:00 p.m. – 7:00 p.m.

Saturday, January 19 7:00 a.m. – 6:00 p.m.

Sunday, January 20 7:30 a.m. – 4:00 p.m.

### **Speaker Ready Room**

Taft Meeting Room on the Mezzanine Level

Friday, January 18 2:00 p.m. – 6:00 p.m.

Saturday, January 19 7:00 a.m. – 5:30 p.m.

Sunday, January 20 7:00 a.m. – 3:00 p.m.

**The meeting organizers ask that all speakers upload their slides four hours prior to their scheduled presentation time.**

**Americans with Disabilities Act** - It is the policy of APSARD not to discriminate against any person based on disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call the Executive Office at 615-649-3083 or send an email to [info@apsard.org](mailto:info@apsard.org).

**APSARD Mobile App** - The APSARD mobile app is now available in the app store for iPhones and in Google Play for Androids. Search APSARD2019 and download today! View the latest schedule, attendee list and abstracts!

# MEETING ANNOUNCEMENTS

## Continuing Education Credits

**Continuing Education Credits** are available for physicians, psychologists, social workers and nurses. Applications for credit must be completed online with the meeting evaluation. The evaluation may be completed after the conference at [www.APSARD.org/meeting/program](http://www.APSARD.org/meeting/program). ***Evaluations for continuing education credit must be submitted no later than February 15, 2019.***

**Disclosures are available for all APSARD Annual Meeting presenters online at [www.APSARD.org/meeting/program](http://www.APSARD.org/meeting/program).** It is the policy of the APSARD to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

## **Accreditation Statements**

This meeting is jointly sponsored by the American Professional Society of ADHD and Related Disorders and AMEDCO.



## **Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. NOTE: If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.



# MEETING ANNOUNCEMENTS



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

## Physicians and Nurses

In support of improving patient care, this activity has been planned and implemented by Amedco, LLC and the American Professional Society of ADHD & Related Disorders (APSARD). Amedco, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Credit Designation Statement – Amedco, LLC designates this live activity for a maximum of 16.25 *AMA PRA Category 1 Credits™* for physicians and 16.25 contact hours for nurses. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## Psychologists

This course is co-sponsored by Amedco and APSARD. Amedco is approved by the American Psychological Association to sponsor continuing education for psychologists. Amedco maintains responsibility for this program. Maximum of 16.25 hours.

**The following state boards accept courses from APA providers for Counselors:** AK, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, MD, ME, MO, NC, ND, NH, NE, NJ, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WI, WY

**AL / Counselors:** Activities not providing NBCC approval may be approved by the Board for individual licensees upon receipt of acceptable documentation prior to the activity. Please send course details to your licensing board for approval BEFORE the event. No approvals afterward by the board.

**MI:** No CE requirements

**The following state boards accept courses from APA providers for MFTs:** AK, AR, AZ, CA, CO, CT, DE, FL, IA, ID, IN, KS, MD, ME, MO, NE, NC, NH, NJ, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WI, WY

## MEETING ANNOUNCEMENTS

**The following state boards accept courses from APA providers for Addictions Professionals:** AK, AR, CO, CT, DC, DE, GA, IA, IN, KS, LA, MD, MO, MT, NC, ND, NE, NJ, NM, NY (outstate held), OK, OR, SC, UT, WA, WI, WY

**MA / MFTs:** Participants can self-submit courses not approved by the MAMFT board for review.

**The following state boards accept courses from APA providers for Social Workers:** AK, AR, AZ, CA, CO, DE, FL, GA, ID, IN, KY, ME, MN, MO, NE, NH, NM, OR, PA, VT, WI, WY

### **Social Workers**

Amedco, #1346, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) [www.aswb.org](http://www.aswb.org), through the Approved Continuing Education (ACE) program. Amedco maintains responsibility for the program. ASWB Approval Period: 6/24/2016 to 6/24/2019. Social workers should contact their regulatory board to determine course approval for continuing education credits. Social workers participating in this course may receive up to 16.25 clinical continuing education clock hours.

**The following state boards accept courses from ASWB providers for Social Workers:** AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, NC, ND, NE, NH, NM, NV, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WI, WY

**The following state boards accept courses from ASWB providers for Counselors:** AK, AR, AZ, CA, CO, CT, DC, FL, GA, IA, ID, IL, IN, KS, MA, MD, ME, MO, ND, NE, NM, NH, NV, OK, PA, TN, TX, UT, VA, WI, WY

**AL / Counselors:** Activities not providing NBCC approval may be approved by the Board for individual licensees upon receipt of acceptable documentation prior to the activity. Please send course details to your licensing board for approval BEFORE the event. No approvals afterward by the board.

**The following state boards accept courses from ASWB providers for MFTs:** AK, AR, AZ, CA, CO, FL, IA, ID, IN, KS, MD, ME, MO, NC, NE, NH, NM, NV, OK, PA, RI, TN, TX, UT, VA, WI, WY

**MA / MFTs:** Participants can self-submit courses not approved by the MAMFT board for review.

## MEETING ANNOUNCEMENTS

**The following state boards accept courses from ASWB providers for Addictions Professionals:** AK, CA, CO, CT, GA, IA, IN, KS, LA, MO, MT, ND, NM, NV, OK, OR, SC, WA, WI, WV, WY

### **ADA Statement**

ADA accommodations will be made in accordance with the law. If you require ADA accommodations, please indicate what your needs are at the time of registration. We cannot ensure the availability of appropriate accommodations without prior notification.

### **Grievances**

If you would like to file a grievance, complaint or have questions, please contact Chelsea McClain at [cmclain@parthenonmgmtm.com](mailto:cmclain@parthenonmgmtm.com).

**All learners who request continuing education credits by February 15, 2019, should expect to receive their statement of credits via email in March.**

**The Meeting Evaluation Survey** will be available at [www.APSARD.org](http://www.APSARD.org). We encourage all registrants to complete the evaluation. Attendees requesting CME, MOC, or CE credits must complete the survey in order to obtain credits. Your candid input on the 2019 meeting is appreciated as we strive to improve the meeting each year.

## MEETING ANNOUNCEMENTS

APSARD would like to acknowledge the generosity of the following companies whose unrestricted educational grants have contributed to the overall quality of this meeting.

**Pfizer**  
**Shire**  
**Sunovion**  
**Supernus Pharmaceuticals**

### **APSARD Society Support**

APSARD would like to thank the following sponsors for their generous donations to the society

#### **Platinum Sponsors**



#### **Silver Sponsors**



#### **Bronze Sponsors**



#### **Exhibitors**

**Please visit the exhibitors in the  
Exhibit Hall C Foyer during the meeting.**

Akili Interactive  
Arbor Pharmaceuticals  
CADDRA  
CHADD  
Ironshore Pharmaceuticals

Qbtech  
Rhodes Pharmaceuticals  
Shire Pharmaceuticals  
Tris Pharmaceuticals  
Vaya Pharmaceuticals

## SCHEDULE AT A GLANCE

### FRIDAY, JANUARY 18, 2019

- 2:00 p.m. - 7:00 p.m.    **APSARD Registration**  
Thurgood Marshall Foyer
- 5:30 p.m. - 7:30 p.m.    **Welcome and Opening Plenary:**  
***New Perspectives on Impulsive Choice***  
***in ADHD: Refining the Phenotype and***  
***Augmenting Therapeutic Options***  
Thurgood Marshall Ballroom
- 7:30 p.m. - 9:00 p.m.    **Reception and Poster Session I**  
Exhibit Hall C

## NOTES

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

# FULL SCHEDULE

## FRIDAY, JANUARY 18, 2019

1:00 p.m. - 3:00 p.m.	<b>APSARD Board Meeting (By Invitation)</b> Hoover
2:00 p.m. - 6:00 p.m.	<b>Speaker Ready Room</b> Taft
2:00 p.m. - 7:00 p.m.	<b>APSARD Registration</b> Thurgood Marshall Foyer
3:00 p.m. - 4:00 p.m.	<b>APSARD Social Media &amp; Education Committee Meeting (By Invitation)</b> Harding
3:00 p.m. - 4:00 p.m.	<b>APSARD Psychosocial Subcommittee Meeting (By Invitation)</b> McKinley
3:00 p.m. - 4:00 p.m.	<b>APSARD Membership Committee Meeting (By Invitation)</b> Coolidge
5:30 p.m. - 7:30 p.m.	<b>Welcome and Opening Plenary:</b> <b><i>New Perspectives on Impulsive Choice in ADHD: Refining the Phenotype and Augmenting Therapeutic Options</i></b> Thurgood Marshall Ballroom

**Chair:** Jeffrey Newcorn, Mount Sinai Medical Center

***Why Are We (Not) Waiting? New Perspectives on the Neuroscience of Impulsive Choice in ADHD.***

Edmund Sonuga-Barke, King's College London

***Pills, Skills and Behaviors: Exploring the Psychopharmacology of Impulsivity***

David Coghill, The University of Melbourne

### **Overall Abstract:**

This session will present new perspectives on the science surrounding impulsive choosing and impulsive behavior in ADHD, and then consider implications for pharmacological treatment. Edmund Sonuga-Barke will

## FULL SCHEDULE

first consider the issue of impulsive choice (i.e., preference for smaller, immediate vs larger, delayed rewards) in the context of motivational deficits in ADHD. He will examine the neuroscience of impulsive choice and present data implicating the limbic and default mode systems in regulating this phenomenon. He will then build a model that provides an integrative view of impulsive choice in ADHD and highlight different ways to interface with the underlying neural systems. Next, David Coghil will examine evidence supporting the complex relationship of impulsivity to ADHD, considering the various models of impulsivity that have been proposed. He will highlight the multiplicity of pathways into impulsivity, and likely different clinical presentations associated with each. He will specifically consider the relationship between cognitive and behavioral impulsivity, and present data regarding pharmacologic treatment in relation to each.

### **Learning Objectives:**

- Attendees will understand the central relevance of impulsive choice and delay aversion to ADHD.
- Attendees will understand the neurobiology underlying impulsive choice and delay aversion in ADHD.
- Attendees will appreciate pharmacologic approaches to the treatment of impulsive choice and delay aversion in ADHD.

7:30 p.m. - 9:00 p.m.

### **Reception and Poster Session I**

Exhibit Hall C

\*\*\*See pages 51-56 for a complete listing of posters.



## SCHEDULE AT A GLANCE

### SATURDAY, JANUARY 19, 2019

7:00 a.m. - 5:30 p.m.	<b>Speaker Ready Room</b> Taft
7:00 a.m. - 6:00 p.m.	<b>APSARD Registration</b> Thurgood Marshall Foyer
7:00 a.m. - 8:00 a.m.	<b>Travel Awardee Breakfast</b> Coolidge
7:30 a.m. - 8:30 p.m.	<b>Morning Break</b> Exhibit Hall C Foyer
8:00 a.m. - 8:45 a.m.	<b>President's Summary: <i>State of APSARD</i></b> Thurgood Marshall Ballroom
9:00 a.m. - 11:00 a.m.	<b>Plenary Session: <i>The Relevance of Biological and Environmental Risk Factors in the ADHD</i></b> Thurgood Marshall Ballroom
11:00 a.m. - 11:30 a.m.	<b>Coffee Break</b> Exhibit Hall C Foyer
11:30 a.m. - 12:30 p.m.	<b>Lifetime Achievement Plenary:</b> <b><i>From LD to ADHD, An Unexpected Journey</i></b> Thurgood Marshall Ballroom
12:30 p.m. - 1:30 p.m.	<b>Data Blitz Session</b> Lincoln 2-4
12:30 p.m. - 2:30 p.m.	<b>Poster Session II with Lunch</b> Exhibit Hall C
2:30 p.m. - 4:30 p.m.	<b>Symposia Sessions</b>  <b><i>Benefits and Challenges of Psychosocial Treatment in ADHD</i></b> Thurgood Marshall Ballroom  <b><i>Risk Factors and Treatment of ADHD and Substance Use Disorders: From Science to Clinical Practice</i></b> Lincoln 2-4

## **SCHEDULE AT A GLANCE**

- 4:30 p.m. - 5:00 p.m.    **Coffee Break**  
Exhibit Hall C Foyer
- 5:00 p.m. - 6:15 p.m.    **Meet the Experts Sessions**  
  
***Psychosocial Topics***  
Lincoln 2-4  
  
***Pharmacotherapy Topics***  
Thurgood Marshall Ballroom
- 6:30 p.m. - 7:30 p.m.    **Reception**  
Exhibit Hall C

# FULL SCHEDULE

## SATURDAY, JANUARY 19, 2019

7:00 a.m. - 5:30 p.m.	<b>Speaker Ready Room</b> Taft
7:00 a.m. - 6:00 p.m.	<b>APSARD Registration</b> Thurgood Marshall Foyer
7:00 a.m. - 8:00 a.m.	<b>Travel Awardee Breakfast</b> Coolidge
7:30 a.m. - 8:30 p.m.	<b>Morning Break</b> Exhibit Hall C Foyer
8:00 a.m. - 8:45 a.m.	<b>President's Summary: <i>State of APSARD</i></b> Thurgood Marshall Ballroom
9:00 a.m. - 11:00 a.m.	<b>Plenary Session: <i>The Relevance of Biological and Environmental Risk Factors in the ADHD</i></b> Thurgood Marshall Ballroom

**Chair:** J.J. Sandra Kooij, PsyQ, Program Adult ADHD, The Hague, The Netherlands

***Catecholamine Regulation of Prefrontal Cortex: Relevance to Etiology and Treatment of ADHD***

Amy Arnsten, Yale School of Medicine

***Using Genetics to Evaluate Environments and Endophenotypes for ADHD***

Joel Nigg, Oregon Health & Science University

***Comorbidity of Attention Deficit Disorder and Physical Conditions: Explanations and Impact***

Kathleen Merikangas, NIH/NIMH

**Overall Abstract:** In this symposium the current state of knowledge on biological and environmental risk factors in ADHD will be discussed, varying from genetics to biomarkers, and from cognitive and physiological measures to comorbidity, and to catecholamines and function of the Prefrontal Cortex.

## FULL SCHEDULE

### Learning Objectives:

- Being updated on the role of cognitive and physiological measures in the pathophysiology of ADHD.
- Learning about the interaction between the Prefrontal Cortex and catecholaminergic activity such as dopaminergic and noradrenergic mechanisms, in relation to medications used in ADHD.

11:00 a.m. - 11:30 a.m. **Coffee Break**  
Exhibit Hall C Foyer

11:30 a.m. - 12:30 p.m. **Lifetime Achievement Plenary:**  
***From LD to ADHD, an Unexpected Journey***  
Thurgood Marshall Ballroom

**Chair:** Joseph Biederman, Massachusetts General Hospital

### ***From LD to ADHD, an Unexpected Journey***

Martha Denckla, Kennedy Krieger Institute/ Neurology at Johns Hopkins University School of Medicine

**Overall Abstract:** The 2019 Lifetime Achievement Award is presented to Professor Martha Denckla. This award recognizes Professor Denckla's extraordinary dedication to the field of ADHD and her contribution to support the science of ADHD and its treatment. Professor Denckla's work focused on the intersection between ADHD, learning disabilities, and executive dysfunction. Her work contributed to advances in the neuropsychological assessment of children, which led to neuroimaging research enhancing the understanding of executive dysfunction in ADHD.

### Learning Objectives:

- To provide an overview of Dr. Denckla's contributions to the field of ADHD.
- To provide an overview on how insights in the understanding of executive dysfunctions advanced the field of ADHD.

## FULL SCHEDULE

12:30 p.m. - 1:30 p.m. **Data Blitz Session**  
Lincoln 2-4

**Chair:** Steven Pliszka, UT Health Science Center at San Antonio

12:30 p.m. – 12:35 p.m. Introduction

12:35 p.m. – 12:39 p.m. ***Human Abuse Potential of Intranasal Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, in Recreational Stimulant Abusers***  
Rene Braeckman, KemPharm, Inc.

12:40 p.m. – 12:44 p.m. ***Motivations and Behaviors of Non-Medical Use of Attention Deficit Hyperactivity Disorder (ADHD) Medications Among Adults***  
Stephen Faraone, SUNY Upstate Medical University

12:45 p.m. – 12:49 p.m. ***Prevalence and Correlates of Attention-Deficit/Hyperactivity Disorder Among Youth with 16p11.2 Copy Number Variation***  
Amandeep Jutla, Columbia University and New York State Psychiatric Institute

12:50 p.m. – 12:54 p.m. ***Treating Clinical and Sub-Clinical Symptoms of ADHD with PCSO-524, A Novel Marine Oil Extract***  
James Kean, Monash University

12:55 p.m. – 12:59 p.m. ***A Pilot MRI Study of Brain-Based Iron Concentrations' Relation to Attention and Cognitive Control***  
Alison Pritchard, Kennedy Krieger Institute

1:00 p.m. – 1:04 p.m. ***A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Crossover, Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults with Attention-Deficit Hyperactivity Disorder (ADHD)***  
Sharon Wigal, AVIDA Inc.

## FULL SCHEDULE

- 1:05 p.m. – 1:09 p.m. ***The Association Between Maternal Antiepileptic Drug Use During Pregnancy and Offspring ADHD***  
Kelsey Wiggs, Indiana University
- 1:10 p.m. – 1:14 p.m. ***Machine-Learning Prediction of Comorbid Substance Use Disorders in ADHD Youth Using Swedish Registry Data***  
Yanli Zhang-James, SUNY Upstate Medical University
- 12:30 p.m. - 2:30 p.m. **Poster Session II with Lunch**  
Exhibit Hall C  
\*\*\*See pages 57-63 for a complete listing of posters.

### Symposia Sessions

- 2:30 p.m. - 4:30 p.m. ***Benefits and Challenges of Psychosocial Treatment in ADHD***  
Thurgood Marshall Ballroom

**Chair:** Russell Barkley, Virginia Commonwealth University Medical Center

#### ***Classroom Behavior Management of ADHD Youth***

Linda Pfiffner, University of California - San Francisco

#### ***Effects and Side Effects of Cognitive-Behavioral Therapy for Adult ADHD***

Laura Knouse, University of Richmond

**Overall Abstract:** A number of approaches to the psychosocial management of ADHD in children and adults have sufficient scientific evidence supporting their effectiveness that they can be considered evidence-based therapies for the disorder. Lacking in this extensive body of research is any widespread or longstanding interest in documenting the adverse events or side effects that may be associated with these interventions. Yet research in psychotherapy and behavioral therapies for the past 50 years has shown that such adverse events are likely to occur, even if in a minority of cases. Based on two special issues of the ADHD Report (February, March 2018) that focused on the side effects of the eight most evidence-based approaches to management of ADHD, this symposium will review the three

## FULL SCHEDULE

most commonly used and science-based psychosocial treatments for child and adult ADHD: parent and family behavior management training for child and adolescent ADHD, classroom behavior management for child and adolescent ADHD, and cognitive behavior therapy for adults with ADHD. Each presenter will note the effectiveness of each intervention and their continuing promise for assisting in the management of the disorder. Yet each presenter will also review the various adverse events that have been documented in research or witnessed in their own implementation of these therapies in their research studies on them. The symposium is designed to encourage a means for conceptualizing these events, more frequent and widespread monitoring and identification of adverse events associated with these therapies, as well as the development of more standardized measures for doing so, similar to what is commonplace in research on ADHD medications.

### **Learning Objectives:**

- Promote understanding of the effectiveness of three major evidence-based psychosocial treatments for ADHD in youth and adults.
- Increase awareness of the nature of and risk for adverse events in parent training and family management.
- Advance understanding of the nature of and risk for adverse events in classroom behavioral management of ADHD.
- Further understanding of the nature of and risk for unwanted or side effects of cognitive behavioral therapy for adults with ADHD.

2:30 p.m. - 4:30 p.m.    ***Risk Factors and Treatment of ADHD and Substance Use Disorders: From Science to Clinical Practice***  
Lincoln 2-4

**Chair:** Frances Levin, Columbia University Medical Center

***Adolescent Developmental Trajectories of Impulse Control and Sensation Seeking and Risk Factors Related to Substance Use***  
Donald Dougherty, UT Health

***ADHD and Opioid Use Disorders: How to Best Intervene***  
Amy Yule, Harvard Medical School/Massachusetts General Hospital

***ADHD-Stimulant Medication Misuse: What is Really Going on?***  
Timothy Wilens, Massachusetts General Hospital

## FULL SCHEDULE

### ***ADHD and Cannabis Use Disorders: Addressing the Comorbidity***

Kevin Gray, Medical University of South Carolina

**Overall Abstract:** Clinicians are often faced with the complexity of assessing and treating adults with ADHD and substance use disorders. Problems of impulse control and early social and environmental factors are crucial in the initiation and maintenance of substance use. Dr. Dougherty will present data demonstrating how pre-adolescent impulse control predicts later substance use and how substance use impacts on the trajectory of impulse control which may, in turn, increase the risk of further substance use involvement. Factors that impact on risk and resiliency will be discussed. Dr. Wilens will then present data from cross-sectional, longitudinal, epidemiological and translational studies of non-medical use of prescription ADHD stimulants in college-aged youth. He will highlight the high rates of stimulant misuse in college settings, short and long-term consequences of use as well as the over-representation of psychiatric comorbidities (e.g., depression, substance use disorders) in stimulant misusers. For individuals diagnosed with both ADHD and a substance use disorder, treatment can be challenging. Two specific groups of interest are those with cannabis use disorders and opioid use disorders. Dr. Yule will provide some background on the opioid epidemic and discuss the clinical challenges in managing individuals with ADHD and opioid use disorders. Dr. Gray will focus the over-representation of cannabis use disorders among those with ADHD. Behavioral and pharmacologic advances in the treatment of cannabis use disorder will be provided as well as practical considerations in working with individuals presenting with both ADHD and cannabis use disorder.

#### **Learning Objectives:**

- To become knowledgeable about the risk factors in childhood associated with substance use along with stimulant misuse in college aged youth.
- To learn about the clinical challenges in the management of ADHD and OUD in intensive SUD treatment programs.
- To become knowledgeable about the recent advances in behavioral and pharmacological treatments for CUD in youth and the clinical consideration for individuals presenting with co-occurring CUD and ADHD.

4:30 p.m. - 5:00 p.m.

#### **Coffee Break**

Exhibit Hall C Foyer



## FULL SCHEDULE

5:00 p.m. - 6:15 p.m. **Meet the Experts Session: *Psychosocial Topics***  
Lincoln 2-4

### **Participants:**

Joseph Blader, University of Texas Health Science Center at San Antonio

Keith McBurnett, University of California, San Francisco

Brooke Molina, University of Pittsburgh

Mary Solanto, Hofstra-Northwell School of Medicine

5:00 p.m. - 6:15 p.m. **Meet the Experts Session: *Pharmacotherapy Topics***  
Thurgood Marshall Ballroom

### **Participants:**

Lenard Adler, NYU School of Medicine

Barbara Coffey, University of Miami Miller School of Medicine

Daniel Gellar, Massachusetts General Hospital

Timothy Wilens, Massachusetts General Hospital

6:30 p.m. - 7:30 p.m. **Reception**  
Exhibit Hall C

## NOTES

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

# SCHEDULE AT A GLANCE

## SUNDAY, JANUARY 20, 2019

7:00 a.m. - 3:00 p.m.	<b>Speaker Ready Room</b> Taft
7:00 a.m. - 4:00 p.m.	<b>APSARD Registration</b> Thurgood Marshall Foyer
7:00 a.m. - 8:00 a.m.	<b>International Attendee Breakfast</b> Coolidge
7:30 a.m. - 8:30 a.m.	<b>Morning Break</b> Exhibit Hall C Foyer
8:15 a.m. - 9:00 a.m.	<b>APSARD Business Meeting and Awards Presentation</b> Thurgood Marshall Ballroom
9:00 a.m. - 10:30 a.m.	<b>Plenary Session: <i>Genetics of ADHD and Implications for Educating Patients and Managing the Disorder</i></b> Thurgood Marshall Ballroom
10:30 a.m. - 11:00 a.m.	<b>Coffee Break</b> Exhibit Hall C Foyer
11:00 a.m. - 12:30 p.m.	<b>Plenary Session: <i>Relevance of Imaging in Understanding ADHD</i></b> Thurgood Marshall Ballroom
12:30 p.m. - 2:30 p.m.	<b>Discussion Groups and Lunch</b>  <b><i>Adult ADHD: Young Adults Through Geriatric</i></b> Lincoln 2-4  <b><i>Imaging and EEG: What Clinicians Should Know</i></b> Thurgood Marshall Ballroom
2:30 p.m. - 4:30 p.m.	<b>Symposia Sessions</b>  <b><i>Seizures, Tics, and OCD in ADHD: Impact on Management</i></b> Lincoln 2-4  <b><i>Bipolar Disorder as It Relates to ADHD</i></b> Thurgood Marshall Ballroom

Sunday,  
January 20, 2019

NOTES

# FULL SCHEDULE

## SUNDAY, JANUARY 20, 2019

7:00 a.m. - 3:00 p.m.	<b>Speaker Ready Room</b> Taft
7:00 a.m. - 4:00 p.m.	<b>APSARD Registration</b> Thurgood Marshall Foyer
7:00 a.m. - 8:00 a.m.	<b>International Attendee Breakfast</b> Coolidge
7:30 a.m. - 8:30 a.m.	<b>Morning Break</b> Exhibit Hall C Foyer
8:15 a.m. - 9:00 a.m.	<b>APSARD Business Meeting and Awards Presentation</b> Thurgood Marshall Ballroom
9:00 a.m. - 10:30 a.m.	<b>Plenary Session: <i>Genetics of ADHD and Implications for Educating Patients and Managing the Disorder</i></b> Thurgood Marshall Ballroom

**Chair:** Russell Schachar, University of Toronto

***What are the Boundaries of ADHD? A Genomic Perspective***

Stephen Faraone, SUNY Upstate Medical University

***Pharmacogenomic Marker Discovery and Delivery of Optimized Medication Treatment Guidance to Improve Care in Child and Adult Psychiatric Disorders***

James Kennedy, Centre for Addiction and Mental Health, University of Toronto

**Overall Abstract:** Our understanding of ADHD is being radically transformed by rapidly accumulating genetic information that addresses key questions. This plenary will provide an update on the implications of modern genetics for our understanding of ADHD. Is ADHD best understood as a disorder or trait? Why do people with this diagnosis have increased risk of other mental and medical conditions? Can genetic testing be used to predict response to currently available treatments and help us find new ones?

## FULL SCHEDULE

### Learning Objectives:

- Learn what recent genetic research tells us about the nature of ADHD?
- Be able to discuss genetic explanations for comorbidity of ADHD, mental and medical illnesses.
- Become familiar with the usefulness of genetic testing for predicting drug response in ADHD.

10:30 a.m. - 11:00 a.m. **Coffee Break**  
Exhibit Hall C Foyer

11:00 a.m. - 12:30 p.m. **Plenary Session: *Relevance of Imaging in Understanding ADHD***  
Thurgood Marshall Ballroom

**Chair:** Philip Asherson, Kings College London

### ***Do ADHD and Autism Overlap in the Brain Connectome? Insights From Neuroimaging***

Adriana Di Martino, The Child Mind Institute

### ***Growing out of ADHD: Insights From Multimodal Imaging***

Philip Shaw, National Human Genome Research Institute

**Overall Abstract:** Neuroimaging studies have opened up new avenues for investigating the structural and functional underpinnings of attention-deficit/hyperactivity disorder (ADHD) and other neurodevelopmental conditions such as autism spectrum disorder (ASD). Multiple cognitive and neural deficits are seen in neurodevelopmental disorders compared to healthy controls, although none have been found to be sufficiently sensitive or specific to be used for diagnostic testing. Another limitation is that current studies do not yet clarify the causal role of the observed deficits: which could reflect genetically correlated neural and cognitive deficits (risk liability markers), or intermediate endophenotypes on the pathway from genes to neurodevelopmental phenotypes. In this symposium we will tackle two key questions. First, to what extent are there similarities or differences in the neuroimaging markers of ADHD and ASD. In general, a consensus has been found that there are considerable differences in the neural and cognitive deficits associated with each disorder, particularly when examined in well characterized clinical samples that separate out the two disorders. Secondly, we examine the neural correlates of persistence and remission when children with ADHD are followed into young adulthood. Here we find

## FULL SCHEDULE

that while some neuroimaging markers are seen in both persisters and remitters, and therefore appear to play no direct role in the adult ADHD phenotypes; other neuroimaging markers are only seen in persistent cases of ADHD and might therefore reflect core processes linked to the symptoms of ADHD in adults. Longitudinal follow-up studies have huge potential to highlight the best targets for treatment.

### **Learning Objectives:**

- Neuroimaging similarities and differences in ADHD and ASD.
- Neuroimaging similarities and differences between persistent and remitted cases of ADHD in young adulthood.
- The causal role of associated neuroimaging findings.

### **Discussion Groups and Lunch**

12:30 p.m. - 2:30 p.m. ***Imaging and EEG: What Clinicians Should Know***

Thurgood Marshall Ballroom

**Chair:** Steven Pliszka, UT Health Science Center at San Antonio  
L. Eugene Arnold, The Ohio State University Nisonger Center  
Edmund Sonuga-Barke, King's College London  
Jonathan Posner, Columbia University

**Overall Abstract:** This session will focus on current issues in the clinical use of EEG, Neurobiofeedback and neuroimaging in mental health. In the first hour, Dr. Gene Arnold will review the recent results of a major controlled study of Neurofeedback in the treatment of ADHD, while Dr. Edmund Sonuga-Barke will discuss the results of the study in the context of his prior metanalysis of the effects of EEG Neurobiofeedback. The audience will be encouraged to share their experience with Neurofeedback in ADHD and related disorders, and a discussion of the appropriate role of Neurofeedback in mental health treatment will ensue. In the second hour, Dr. Jonathan Posner will present the basic principles of neuroimaging for the non-researcher. He will summarize the challenges in developing clinically applicable neuroimaging and give a sense of future directions in the field. There will then be time for extended discussion and questions from the audience; particularly with regard to how to speak to families and patients regarding this issue.

## FULL SCHEDULE

### Learning Objectives:

- Discuss the results of controlled studies of EEG Neurofeedback in the treatment of ADHD.
- Answer patient and family questions and engage in shared-decision making regarding EEG Neurobiofeedback in ADHD.
- Understand the challenges and limitations of modern neuroimaging in mental health Learning.
- Discuss what to tell a family who ask for a “Brain scan” of their child with ADHD.

12:30 p.m. - 2:30 p.m. ***Adult ADHD: Young Adults through Geriatric***  
Lincoln 2-4

**Chair:** Iris Manor, Geha MHC

Craig Surman, Massachusetts General Hospital

J. Russell Ramsay, University of Pennsylvania, Perelman School of Medicine

**Overall Abstract:** ADHD is a chronic, life time, impairing disorder, and still its evaluation, and to a large extent its treatment, is based on symptoms. This issue is even more important since several studies have already demonstrated that symptoms and impairment are not correlated enough. This discrepancy is demonstrated while looking for persistence vs. remission of ADHD: the percentage of symptomatic remission is significantly different than that of impairment remission (Biederman et al. 2000). Moreover, adults with ADHD, who tend according to the literature to have fewer symptoms, are even more impaired than children and adolescents when they are measured by objective measures, such as the CPT (Ben Sheetrit et al, 2017) The treatment of ADHD is heavily influenced by this discrepancy, since when a patient is treated, they are usually treated according to their symptoms, which doesn't necessarily mean treating their impairment. Van Lisehout et al (2013) found that Both “remitters” and “persisters” tended to show weaker performance compared to controls, although the “remitters” tended to perform better than the “persisters”. Adults also tend to have a significant and unstable symptomatic placebo response as they are measured by the CAARS or the ASRS (Ben Sheetrit et al, 2018). Their placebo response to treatment in light of impairment, as is measured by objective measures, seems different (unpublished data) and the response to treatment correlation between symptoms solving and impairment solving is weak. Hence, the issue of impairment vs. symptoms has meaningful implications on the clinical picture as well as the treatment plan and deserves to be discussed.



## FULL SCHEDULE

### Learning Objectives:

- Impairment as a separate and meaningful construct in ADHD.
- The difference in the dynamics of symptoms and impairment with age.
- Treatment of adult ADHD; aimed to symptoms improvement or impairment improvement.

### Symposia Sessions

2:30 p.m. - 4:30 p.m.    ***Seizures, Tics, and OCD in ADHD: Impact on Management***  
Lincoln 2-4

**Chair:** Steven Pliszka, UT Health Science Center at San Antonio

#### ***ADHD and Tics: Boundaries, Overlap and Disentanglement***

Barbara Coffey, University of Miami Miller School of Medicine

#### ***Epilepsy and Psychiatric Disorders: Bidirectional Interface and Opportunity***

Joseph Gonzalez-Heydrich, Boston Children's Hospital

#### ***Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents with Obsessive Compulsive Disorder (OCD): Fact or Artifact?***

Daniel Geller, Massachusetts General Hospital

**Overall Abstract:** Tics, OCD and seizures occupy a boundary between neurology and psychiatry. Each present clinical challenge when they are comorbid with ADHD. This symposium will present recent findings and advice for clinical management for each of these presentations. Dr. Coffey will examine issues regarding tics in ADHD, including the overlapping neurobiology between ADHD and tic disorders in both genetic and neuroimaging studies. She will present current thinking on both the pharmacological and psychosocial treatment of tics in the presence of ADHD in order to optimize treatment of both disorders. Dr. Gonzalez-Heydrich will speak on the bidirectional interface of epilepsy and ADHD. ADHD often precedes and increases risk for epilepsy arguing for an underlying vulnerability to both in many patients. Genetic and environmental insults to the mechanisms of neurodevelopment that can lead to weakness of executive circuitry and cause ADHD, increase risk of epilepsy, and lead to comorbid ADHD and epilepsy. Rare genetic syndromes

## FULL SCHEDULE

associated with ADHD, epilepsy and combined ADHD+epilepsy point to these neuropathological mechanisms. He will describe how ADHD is undertreated in those with epilepsy due to unreasonable fears of the effects of ADHD medications on seizures and discuss the effects of anti-epileptic drugs (AEDs) on attention. In addition, Dr. Daniel Geller will examine the comorbidity of OCD and ADHD, presenting data from a large cohort (n=121) of ADHD patients with and without OCD. This study suggests that when ADHD-like symptoms are seen in OCD youth they reflect a true comorbid state of OCD plus ADHD and that the ADHD syndrome may be independent of OCD in comorbid youth. Attention to both disorders is needed to assure best clinical outcomes.

### **Learning Objectives:**

- Understanding the overlapping neurobiology of tics and ADHD.
- Discuss the genetic and environmental risk factors that may interact in patient with both epilepsy and ADHD.
- Discuss the effects of anti-epileptic drugs on cognition and understand the risk/benefits of the use of ADHD medications in patient with epilepsy.
- Understand the nature of the comorbidity of OCD and ADHD and its implication for the treatment of both disorders.

2:30 p.m. - 4:30 p.m.    ***Bipolar Disorder as It Relates to ADHD***  
Thurgood Marshall Ballroom

**Chair:** Janet Wozniak, Mass General Hospital

### ***Predictive Utility of the CBCL Bipolar Profile***

Joseph Biederman, Massachusetts General Hospital

### ***Comorbidity with ADHD and Course in a Spanish Sample of Children & Adolescents with Bipolar Disorder***

César Soutullo, University of Navarra Clinic

### ***Familial Aggregation and Co-Aggregation of Bipolar Disorder and ADHD***

Kathleen Merikangas, NIH/NIMH

**Overall Abstract:** This symposium will address practice-changing advances in the research and understanding of pediatric bipolar disorder and ADHD. Dr Wozniak will provide an overview of pediatric bipolar disorder as a valid diagnosis and provide evidence-based findings regarding its co-occurrence

## FULL SCHEDULE

with ADHD. She will review data from clinic and research settings. She will provide information on familiarity, course, treatment response and biomarker studies which support the validity of the comorbid condition pediatric bipolar disorder and ADHD.

### **Learning Objectives:**

- Pediatric bipolar disorder is a valid diagnosis with predictable course and clinical characteristics.
- Family genetic studies support the co-occurrence of pediatric bipolar disorder and ADHD.
- Pediatric bipolar disorder has a persistent course.
- Treatment outcomes and biomarker research support the validity of the bipolar and ADHD.

## NOTES

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

## POSTERS

Friday, January 18, 2019

7:30 p.m. – 9:00 p.m.

Reception and Poster Session I

### **F1. A Modified-Release Drug Delivery Technology Containing Amphetamine-Ion Exchange Complexes**

Barry Herman<sup>1</sup>, Thomas King<sup>\*1</sup>, Judith Kando<sup>1</sup>, Antonio Pardo<sup>1</sup>

<sup>1</sup>Tris Pharma, Inc.

### **F2. Single Dose Pharmacokinetics of Amphetamine Extended-Release Oral Suspension (AMPH EROS) in Children Aged 4 to 5 Years old With Attention-Deficit/Hyperactivity Disorder**

Barry Herman<sup>1</sup>, Andrea Marraffino<sup>2</sup>, Judith Kando<sup>1</sup>, Thomas King<sup>\*1</sup>, Antonio Pardo<sup>1</sup>, Andrew J. Cutler<sup>3</sup>

<sup>1</sup>Tris Pharma, Inc. <sup>2</sup>Florida Clinical Research Center, LLC, <sup>3</sup>Meridien Research

### **F3. AKL-T01, A Novel, Digital Treatment for ADHD Reduces Ex-Gaussian Tau and Induces a Shift in Response Criterion in an Objective Test of Attention**

Stephen Faraone<sup>\*1</sup>, Scott Kollins<sup>2</sup>, Elena Cañadas<sup>3</sup>, Jeffrey D. Bower<sup>3</sup>, Jeffrey Epstein<sup>4</sup>, Denton DeLoss<sup>3</sup>

<sup>1</sup>SUNY Upstate Medical University, <sup>2</sup>Duke University, <sup>3</sup>Akili Interactive,

<sup>4</sup>Cincinnati Children's Hospital Medical Center

### **F4. Sleep-Associated Adverse Events During Methylphenidate Treatment of Attention-Deficit/Hyperactivity Disorder in Youth: A Meta-Analysis**

Stephen Faraone<sup>\*1</sup>, Michelle Po<sup>2</sup>, Marina Komolova<sup>2</sup>, Samuele Cortese<sup>3</sup>

<sup>1</sup>SUNY Upstate Medical University, <sup>2</sup>Ironshore Pharmaceuticals and Development, Inc., <sup>3</sup>Center for Innovation in Mental Health, University of Southampton

### **F5. Relationships Among Score Changes on the Brown Attention-Deficit Disorder Scale in Adults With ADHD: Post-Hoc Analyses of two SHP465 Mixed Amphetamine Salts Extended-Release Clinical Trials**

Thomas Brown<sup>\*1</sup>, Jie Chen<sup>2</sup>, Brigitte Robertson<sup>2</sup>

<sup>1</sup>Keck School of Medicine of University of Southern California, <sup>2</sup>Shire

## POSTERS

### **F6. Response Profile of a Novel, Home-Based, Digital Treatment for Pediatric Attention-Deficit/Hyperactivity Disorder**

Scott Kollins<sup>\*1</sup>, Elena Canadas<sup>2</sup>, Ann Childress<sup>3</sup>, Raun Melmed<sup>4</sup>, Denton DeLoss<sup>2</sup>, Jacqueline Lutz<sup>2</sup>

<sup>1</sup>Duke University, <sup>2</sup>Akili Interactive, <sup>3</sup>Spring Mountain Treatment Center and Montevista Hospital, <sup>4</sup>Melmed Center

### **F7. Post-Hoc Analyses of Remission from two Studies of SHP465 Mixed Amphetamine Salts Extended-Release in Adults With Attention-Deficit/Hyperactivity Disorder**

Lenard Adler<sup>\*1</sup>, Jie Chen<sup>2</sup>, Brigitte Robertson<sup>2</sup>, Richard Able<sup>2</sup>, Elias Sarkis<sup>3</sup>

<sup>1</sup>NYU School of Medicine, <sup>2</sup>Shire, <sup>3</sup>Sarkis Family Psychiatry

### **F8. Efficacy and Safety of DR/ER-MPH, A Delayed-Release and Extended-Release Methylphenidate, in Children With ADHD: Results From a Pivotal Phase 3 Classroom Trial**

Ann Childress<sup>\*1</sup>, Andrew J. Cutler<sup>2</sup>, Andrea Marraffino<sup>2</sup>, Norberto DeSousa<sup>3</sup>, Bev Incledon<sup>3</sup>, Randy Sallee<sup>3</sup>

<sup>1</sup>Center for Psychiatry and Behavioral Medicine, Inc., <sup>2</sup>Meridien Research, <sup>4</sup>Ironshore Pharmaceuticals and Development, Inc.

### **F9. Single-Dose Pharmacokinetics of KP415, An Investigational Product Containing the Prodrug Serdexmethylphenidate (SDX), in Children and Adolescents With ADHD**

Rene Braeckman<sup>\*1</sup>, Sven Guenther<sup>1</sup>, Travis Mickle<sup>1</sup>, Andrew Barrett<sup>1</sup>, Adam Smith<sup>1</sup>, Wei Zhang<sup>2</sup>, Kathryn Roupe<sup>2</sup>

<sup>1</sup>KemPharm, Inc., <sup>2</sup>Worldwide Clinical Trials

### **F10. Dose-Proportionality and Steady-State Pharmacokinetics of KP415, an Investigational ADHD Product Containing Serdexmethylphenidate (SDX), A Novel Prodrug of D-Methylphenidate**

Rene Braeckman<sup>\*1</sup>, Sven Guenther<sup>1</sup>, Travis Mickle<sup>1</sup>, Andrew Barrett<sup>1</sup>, Adam Smith<sup>1</sup>, Wei Zhang<sup>2</sup>, Kathryn Roupe<sup>2</sup>, Cynthia Zamora<sup>2</sup>

<sup>1</sup>KemPharm, Inc., <sup>2</sup>Worldwide Clinical Trials

### **F11. A Novel Text Message Intervention to Improve Adherence to Stimulants in Adults With ADHD**

Ronna Fried<sup>\*1</sup>, Maura Fitzgerald<sup>2</sup>, Yvonne Woodworth<sup>2</sup>, Itai Biederman<sup>2</sup>, Elizabeth Noyes<sup>2</sup>, Stephen Faraone<sup>3</sup>, Joseph Biederman<sup>1</sup>

<sup>1</sup>Massachusetts General Hospital and Harvard Medical School,

<sup>2</sup>Massachusetts General Hospital, <sup>3</sup>SUNY Upstate Medical University

## POSTERS

### **F12. Trajectories of Clinical Change Mechanisms in a Cognitive Behavioral Intervention for College Students With ADHD**

Laura Eddy\*<sup>1</sup>, Arthur Anastopoulos<sup>1</sup>, Joshua Langberg<sup>2</sup>, Paul Silvia<sup>1</sup>

<sup>1</sup>University of North Carolina , <sup>2</sup>Virginia Commonwealth University

### **F13. Treatment-Emergent Affective Adverse Effects of Three Stimulant Preparations**

Joseph Blader\*<sup>1</sup>, Steven Pliszka<sup>1</sup>, Vivian Kafantaris<sup>2</sup>

<sup>1</sup>University of Texas Health Science Center at San Antonio, <sup>2</sup>Zucker Hillside Hospital

### **F14. Subtle Motor Signs as a Biomarker for Effective Mindful Movement Intervention in Children With ADHD**

Stewart Mostofsky\*<sup>1</sup>, Dav Clark<sup>2</sup>, Robert Findling<sup>3</sup>

<sup>1</sup>Center for Neurodevelopmental and Imaging Research, <sup>2</sup>Glass Bead Labs, Gigantum, <sup>3</sup>Johns Hopkins University

### **F15. Perceived Stigma and the Positive Illusory Bias in Children With ADHD**

Avery Albert\*<sup>1</sup>, Lea Taylor<sup>1</sup>, Laurie Boucicaut<sup>1</sup>, Jessica Simmons<sup>1</sup>, Kevin Antshel<sup>1</sup>

<sup>1</sup>Syracuse University

### **F16. Medication Acceptance Among African American Parents of Children With ADHD**

Amy Glasofer\*<sup>1</sup>

<sup>1</sup>Virtua

### **F17. Factors Associated With ADHD Medication Use in Community Care Settings**

Kelly Kamimura-Nishimura\*<sup>1</sup>, Jeffrey Epstein<sup>1</sup>, Tanya Froehlich<sup>1</sup>, James Peugh<sup>1</sup>, William Brinkman<sup>1</sup>, Rebecca Baum<sup>2</sup>, William Gardner<sup>3</sup>, Joshua Langberg<sup>4</sup>, Phil Lichtenstein<sup>5</sup>, David Chen<sup>2</sup>, Kelly Kelleher<sup>2</sup>

<sup>1</sup>Cincinnati Children's Hospital Medical Center, <sup>2</sup>Nationwide Children's Hospital, <sup>3</sup>Children's Hospital of Eastern Ontario, <sup>4</sup>Virginia Commonwealth University, <sup>5</sup>The Children's Home of Cincinnati

## POSTERS

### **F18. ADHD Coaching Modes of Delivery: Frequency and Efficacy**

Elizabeth Ahmann\*<sup>1</sup>, Micah Saviet<sup>2</sup>

<sup>1</sup>Maryland University of Integrative Health, <sup>2</sup>University of Maryland School of Social Work

### **F19. Sluggish Cognitive Tempo (SCT) Prevalence Rates in an ADHD-Referred Outpatient Sample: Impact of Reporting Source and Functional Impairment Criterion**

John Mitchell\*<sup>1</sup>, Jessica Lunsford-Avery<sup>1</sup>, Naomi Davis<sup>1</sup>, Scott Kollins<sup>1</sup>

<sup>1</sup>Duke University Medical Center

### **F20. Eveningness Diurnal Preference: Putting the “Sluggish” in Sluggish Cognitive Tempo Among Adult Outpatients?**

Jessica Lunsford-Avery\*<sup>1</sup>, John Mitchell<sup>1</sup>, Maggie Sweitzer<sup>1</sup>, Scott Kollins<sup>1</sup>

<sup>1</sup>Duke University Medical Center

### **F21. Collateral Ratings of Childhood Symptoms Among Adult Outpatients Seeking an Evaluation for ADHD**

Naomi Davis\*<sup>1</sup>, John Mitchell<sup>1</sup>, Jessica Lunsford-Avery<sup>1</sup>, Scott Kollins<sup>1</sup>

<sup>1</sup>Duke University Medical Center

### **F22. Self- Versus Collateral Informant-Reported Symptoms of ADHD, Anger-Irritability, and Impairment in Adulthood in a Longitudinally Followed Sample of Children With ADHD**

Brooke Molina\*<sup>1</sup>, Rachel Lindstrom<sup>2</sup>, Neil Jones<sup>1</sup>, Amelia Versace<sup>1</sup>, Cecile Ladouceur<sup>1</sup>, Elizabeth Gnagy<sup>3</sup>, Tracey Wilson<sup>2</sup>, William Pelham<sup>3</sup>

<sup>1</sup>University of Pittsburgh, <sup>2</sup>University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, <sup>3</sup>Florida International University

### **F23. The Validity of Adult – Onset ADHD: A Critical Analysis**

Lea Taylor\*<sup>1</sup>, Avery Albert<sup>1</sup>, Rachel Lighthall<sup>1</sup>, Jessica Simmons<sup>1</sup>, Kevin Antshel<sup>1</sup>

<sup>1</sup>Syracuse University

### **F24. Machine Learning Classification of Attention Deficit Hyperactivity Disorder Using Structural MRI Data**

Yanli Zhang-James\*<sup>1</sup>, Barbara Franke<sup>2</sup>, Martine Hoogman<sup>2</sup>, Stephen Faraone<sup>1</sup>, Emily Helminen<sup>3</sup>

<sup>1</sup>SUNY Upstate Medical University, <sup>2</sup>Radboud University Medical Center,

<sup>3</sup>Syracuse University



## POSTERS

### **F25. Avoidance Behavior in Patients With Comorbid PTSD and ADHD**

Sachintha Lokuge\*<sup>1</sup>, Emilia Sherifi<sup>1</sup>, Kathryn Fotinos<sup>1</sup>, Zahra Khan<sup>1</sup>, Sarah Drury<sup>1</sup>, Tia Sternat<sup>1</sup>, Irvin Epstein<sup>1</sup>, Catherine Cameron<sup>1</sup>, Isaac Szpindel<sup>1</sup>, Martin Katzman<sup>1</sup>

<sup>1</sup>START Clinic for Mood and Anxiety Disorders

### **F26. Maternal ADHD Symptoms and Risks for Problematic Eating Behavior in Children**

Julia Schechter\*<sup>1</sup>, Bernard Fuemmeler<sup>2</sup>, Nancy Zucker<sup>1</sup>, Julianna Becker<sup>1</sup>, Logan Smith<sup>1</sup>, Susan Murphy<sup>1</sup>, Cathrine Hoyo<sup>3</sup>, Scott Kollins<sup>1</sup>

<sup>1</sup>Duke University Medical Center, <sup>2</sup>Virginia Commonwealth University,

<sup>3</sup>North Carolina State University

### **F27. Exploring Attention and Drinking Behaviors in College Students: Baseline Characteristics**

Mariely Hernandez\*<sup>1</sup>, Sarah Scherrer<sup>1</sup>, Geneva Hidalgo<sup>1</sup>, Sarah O'Neill<sup>1</sup>

<sup>1</sup>The City College of New York/CUNY Graduate Center

### **F28. Associations Among Children's ADHD Severity, Parenting Stress and Socioeconomic Status Across Early Childhood**

Ramya Jayanthi\*<sup>1</sup>, Sarah O'Neill<sup>1</sup>, Shelagh Mahbubhani<sup>1</sup>, Elias Collado<sup>1</sup>, Khushmand Rajendran<sup>1</sup>, Jeffrey Halperin<sup>2</sup>

<sup>1</sup>City College of New York, <sup>2</sup>Queens College

### **F29. ADHD Symptom Severity and Parental Self-Efficacy in a Mixed Clinical Sample**

Corina Zisman\*<sup>1</sup>, Natalie Ridgely<sup>1</sup>, Erin Jones<sup>1</sup>, Lisa Jacobson<sup>1</sup>, Alison Pritchard<sup>1</sup>, T. Andrew Zabel<sup>1</sup>

<sup>1</sup>Kennedy Krieger Institute

### **F30. PHQ-9 Reduction and Relief From Depressive Symptoms With Psychostimulant Monotherapy**

Jesse McClelland\*<sup>1</sup>, Kimi Hashimoto<sup>1</sup>, Joshua Potter<sup>1</sup>

<sup>1</sup>Psychiatry Northwest and TMS Washington

### **F31. Women and ADHD Functional Impairments: Beyond the Obvious**

Noelle Lynn\*<sup>1</sup>

<sup>1</sup>Grand Valley State University

## POSTERS

### **F32. Genes and Brain Cell Types Linked With Selective Neuronal Vulnerability in ADHD**

Jonathan Hess\*<sup>1</sup>, Jameson Patak<sup>1</sup>, Stephen Faraone<sup>1</sup>, Stephen Glatt<sup>1</sup>  
<sup>1</sup>SUNY Upstate Medical University

### **F33. Association Between DRD4 Methylation and Response to Methylphenidate and Placebo in Children With ADHD**

Weam Fageera\*<sup>1</sup>, Boris Chaumette<sup>2</sup>, Natalie Grizenko<sup>2</sup>, Sarojini M. Sengupta<sup>2</sup>, Ridha Joober<sup>2</sup>  
<sup>1</sup>McGill University, <sup>2</sup>Douglas Mental Health University Institute

### **F34. Neural Mechanisms Underlying the Therapeutic Actions of PS-Omega-3 Fatty Acid Supplementation in Adults With ADHD**

Kurt Schulz\*<sup>1</sup>, Beth Krone<sup>1</sup>, Lenard Adler<sup>2</sup>, Stephen Faraone<sup>3</sup>, Jeffrey Newcorn<sup>4</sup>  
<sup>1</sup>Icahn School of Medicine at Mount Sinai, <sup>2</sup>NYU School of Medicine, <sup>3</sup>SUNY Upstate Medical University, <sup>4</sup>Mount Sinai Medical Center

### **F35. The Efficacy of Phosphatidylserine in the Treatment of Pediatric Attention-Deficit/Hyperactivity Disorder (ADHD): A Systematic Review and Meta-Analysis**

Alisha Bruton\*<sup>1</sup>  
<sup>1</sup>NUNM

### **F36. Magnesium L-Threonate Supplementation in ADHD: An Open-Label Pilot Study of Cognitive and Functional Effects**

Craig Surman\*<sup>1</sup>, Carrie Vaudreuil<sup>1</sup>, Heidi Boland<sup>1</sup>, Lauren Rhodewalt<sup>1</sup>, Maura DiSalvo<sup>1</sup>, Joseph Biederman<sup>1</sup>  
<sup>1</sup>Massachusetts General Hospital

## POSTERS

Saturday, January 19, 2019

12:30 p.m. – 2:30 p.m.

Poster Session II with Lunch

### **S1. A Pharmacokinetic Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR®) in Male and Female Preschool Children 4 to Under 6 Years of Age With Attention Deficit Hyperactivity Disorder Under Fed Conditions**

Akwete Adjei\*<sup>1</sup>, Inder Chaudhary<sup>1</sup>, Nathan Teuscher<sup>2</sup>, Ed Freshwater<sup>2</sup>, Scott Kollins<sup>3</sup>, Americo Padilla<sup>4</sup>, Robert J. Kupper<sup>1</sup>

<sup>1</sup>Rhodes Pharmaceuticals, <sup>2</sup>Certara, <sup>3</sup>Duke University, <sup>4</sup>Niklaus Children's Hospital

### **S2. A Phase 4, Open-Label, Multicenter, Single-Dose Study of the Pharmacokinetics of a Novel Amphetamine Extended-Release Oral Disintegrating Tablet Formulation (AMP XR-ODT™) in Preschool-Aged Children**

Carolyn Sikes\*<sup>1</sup>, Rob Riesenbergs<sup>2</sup>, Andrea Marraffino<sup>3</sup>, Dorothy Engelking<sup>1</sup>, Thomas Laage<sup>5</sup>, Andrew Volosov<sup>5</sup>, Alison Hart<sup>5</sup>

<sup>1</sup>Neos Therapeutics, <sup>2</sup>Atlanta Center for Medical Research, <sup>3</sup>Meridien Research, <sup>4</sup>Premier Research

### **S3. Improvements in At-Home Functional Impairment With DR/ER-MPH in Children With ADHD: Post Hoc Analysis of BSFQ and PREMB-R by Norm-Referenced Cut-Offs**

Stephen Faraone<sup>1</sup>, Timothy Wilens<sup>2</sup>, Steven Pliszka<sup>3</sup>, Norberto DeSousa<sup>4</sup>, Randy Sallee\*<sup>4</sup>, Bev Incledon<sup>4</sup>, Jeffrey Newcorn<sup>5</sup>

<sup>1</sup>SUNY Upstate Medical University, <sup>2</sup>Harvard Medical School/Massachusetts General Hospital, <sup>3</sup>UT Health Science Center at San Antonio, <sup>4</sup>Ironshore Pharmaceuticals and Development, Inc., <sup>5</sup>Mount Sinai Medical Center

### **★ S4. A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Crossover, Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)**

Sharon Wigal\*<sup>1</sup>, Timothy Wigal<sup>1</sup>, Matthew Leoni<sup>2</sup>, Mary Hobart<sup>2</sup>, Jessica Madera<sup>2</sup>, Ross Baker<sup>2</sup>, Robert McQuade<sup>2</sup>

<sup>1</sup>AVIDA Inc., <sup>2</sup>Otsuka (OPDC)

★ Data Blitz

## POSTERS

### **S5. Comparative Analysis of the Efficacy of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With ADHD Using a Model-Informed Approach**

Roberto Gomeni<sup>\*1</sup>, Francoise Bressolle<sup>1</sup>

<sup>1</sup>PharmacoMetrica

### **S6. Rationale and Design of Three Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate the Efficacy and Safety of SPN-810 (Extended-Release Molindone) for the Treatment of Impulsive Aggression in Youths With ADHD**

Gianpiera Ceresoli-Borroni<sup>\*1</sup>, Toyin Adewole<sup>1</sup>, Tesfaye Liranso<sup>1</sup>, Jiahong Xu<sup>1</sup>, Fatima Chowdhry<sup>1</sup>, Azmi Nasser<sup>1</sup>

<sup>1</sup>Supernus Pharmaceuticals, Inc.

### **★ S7. Human Abuse Potential of Intranasal Serdexmethylphenidate (SDX), A Novel Prodrug of d-Methylphenidate, in Recreational Stimulant Abusers**

Rene Braeckman<sup>\*1</sup>, Sven Guenther<sup>1</sup>, Travis Mickle<sup>1</sup>, Andrew Barrett<sup>1</sup>, Beatrice Setnik<sup>2</sup>

<sup>1</sup>KemPharm, Inc., <sup>2</sup>Syneos Health

### **S8. Human Abuse Potential of Oral Serdexmethylphenidate (SDX), A Novel Prodrug of d-Methylphenidate, Compared to Focalin®XR and Phentermine in Recreational Stimulant Abusers**

Rene Braeckman<sup>\*1</sup>, Sven Guenther<sup>1</sup>, Travis Mickle<sup>1</sup>, Andrew Barrett<sup>1</sup>, Lynn Webster<sup>2</sup>

<sup>1</sup>KemPharm, Inc., <sup>2</sup>PRA Health Sciences

### **S9. Open-Label Dose-Optimization of an Amphetamine Extended-Release Oral Suspension in Children With Attention-Deficit/Hyperactivity Disorder**

Andrew J. Cutler<sup>1</sup>, Antonio Pardo<sup>2</sup>, Thomas King<sup>\*2</sup>, Judith Kando<sup>2</sup>, Barry Herman<sup>2</sup>

<sup>1</sup>Meridien Research, <sup>2</sup>Tris Pharma, Inc.

### **★ S10. Treating Clinical and Sub-Clinical Symptoms of ADHD With PCSO-524, A Novel Marine Oil Extract**

James Kean<sup>\*1</sup>

<sup>1</sup>Monash University

### **★ Data Blitz**

## POSTERS

### **S11. An Innovative SMS Intervention to Improve Adherence to Stimulants in Children With ADHD**

Ronna Fried\*<sup>1</sup>, Maura DiSalvo<sup>2</sup>, Yvonne Woodworth<sup>2</sup>, Itai Biederman<sup>2</sup>, Caroline Kelberman<sup>2</sup>, Stephen Faraone<sup>3</sup>, Amos Adler<sup>4</sup>, Debra McCafferty<sup>4</sup>, Joseph Biederman<sup>1</sup>

<sup>1</sup>Massachusetts General Hospital and Harvard Medical School,

<sup>2</sup>Massachusetts General Hospital, <sup>3</sup>SUNY Upstate Medical University and University of Bergen, <sup>4</sup>MEMOTEXT Corporation

### **S12. Problems With Emotional Control in Children With ADHD Predicts Co-Occurring Internalizing Problems in Girls and Externalizing Problems in Girls and Boys in Adolescence**

Abigail Benjamin\*<sup>1</sup>, Karen Seymour<sup>2</sup>, Carolyn Koch<sup>1</sup>, Stewart Mostofsky<sup>1</sup>, Keri Rosch<sup>3</sup>

<sup>1</sup>Kennedy Krieger Institute, <sup>2</sup>Johns Hopkins University School of Medicine,

<sup>3</sup>Kennedy Krieger Institute/Johns Hopkins

### **S13. Mind Wandering in ADHD, A Literature Review**

Jane Lanier\*<sup>1</sup>, Elizabeth Noyes<sup>2</sup>, Joseph Biederman<sup>1</sup>

<sup>1</sup>Massachusetts General Hospital and Harvard Medical School,

<sup>2</sup>Massachusetts General Hospital

### **S14. Sensitivity to Reward Predicts Improvement in Inhibitory Control With Reward Among College Students With ADHD and Alcohol-Related Problems**

Joshua Robinson\*<sup>1</sup>, Keri Rosch<sup>2</sup>, Karen Seymour<sup>3</sup>, John Vasko<sup>4</sup>, Michael Meinzer<sup>5</sup>, Lauren Oddo<sup>5</sup>, Andrea Chronis-Tuscano<sup>5</sup>

<sup>1</sup>Kennedy Krieger Institute, <sup>2</sup>Kennedy Krieger Institute/Johns Hopkins,

<sup>3</sup>Johns Hopkins University School of Medicine, <sup>4</sup>University of Wyoming,

<sup>5</sup>University of Maryland

### **S15. Impaired Goal-Directed Behavior in Children With Attention-Deficit/Hyperactivity Disorder**

Joman Natsheh\*<sup>1</sup>, Mousa Mustafa<sup>2</sup>, Al-Ashhab Motee<sup>2</sup>, Michael Shiflett<sup>3</sup>, Mark Gluck<sup>3</sup>, Ekaterina Dobryakova<sup>1</sup>, John DeLuca<sup>1</sup>, Mohammad Herzallah<sup>2</sup>

<sup>1</sup>Kessler Foundation, <sup>2</sup>Al-Quds University, <sup>3</sup>Rutgers University

## POSTERS

### **S16. Building Peer Relationships in ADHD Using the Summer Treatment Program**

Benjamin Aaronson<sup>\*1</sup>, Hannah Bolotin<sup>1</sup>, Will McCloud<sup>1</sup>, Tyler Sasser<sup>1</sup>, Jeffrey Munson<sup>1</sup>, Mark Stein<sup>1</sup>, Annette Estes<sup>1</sup>

<sup>1</sup>University of Washington

### **S17. Eveningness Diurnal Preference and Cannabis Use Among Adults Seeking an ADHD Evaluation**

Jessica Lunsford-Avery<sup>\*1</sup>, Maggie Sweitzer<sup>1</sup>, Scott Kollins<sup>1</sup>, John Mitchell<sup>1</sup>

<sup>1</sup>Duke University Medical Center

### **S18. Stimulant-Induced Psychosis - How Does It Present in Clinic and What Are the Risk Factors? Two Case Reports and a Literature Review**

Aaron Winkler<sup>\*1</sup>

<sup>1</sup>University of Maryland / Sheppard Pratt

### **S19. The Predictive Utility of Retrospective Self-Report of Early Temperament for ADHD Diagnostic Status in Adulthood**

Jessica Sloan<sup>\*1</sup>, Cara Lusby<sup>1</sup>, Logan Smith<sup>1</sup>, Julianna Becker<sup>1</sup>, Scott Kollins<sup>1</sup>

<sup>1</sup>Duke University Medical Center

### **★ S20. Machine-Learning Prediction of Comorbid Substance Use Disorders in ADHD Youth Using Swedish Registry Data**

Yanli Zhang-James<sup>\*1</sup>, Qi Chen<sup>2</sup>, Henrik Larsson<sup>2</sup>, Stephen Faraone<sup>1</sup>

<sup>1</sup>SUNY Upstate Medical University, <sup>2</sup>Karolinska Institutet

### **S21. Gender Differences in ADHD Subtype Distribution in the Puerto Rican Youth Population**

Alex Luna<sup>\*1</sup>, Joel Bernanke<sup>2</sup>, Thomas Corbeil<sup>3</sup>, Jonathan Posner<sup>4</sup>, Cristiane Duarte<sup>4</sup>

<sup>1</sup>Columbia University, <sup>2</sup>Weill Cornell Medical Center, <sup>3</sup>Mailman School of Public Health, <sup>4</sup>New York State Psychiatric Institute

### **S22. How ADHD Symptoms Relate to Word Reading and Reading Comprehension**

Masha Jones<sup>\*1</sup>, Osman Umarji<sup>1</sup>, Francesca Trane<sup>1</sup>, Elham Zargar<sup>1</sup>, Stephanie Day<sup>1</sup>, Carol Connor<sup>1</sup>

<sup>1</sup>University of California Irvine

### **★ Data Blitz**

## POSTERS

### **S23. Investigating the Relationship Between Objective and Subjective Evaluations of Treatment Optimization in Individuals With ADHD**

Perry Roy\*<sup>1</sup>, R. Derek Brugman<sup>1</sup>, Amy Stevenson<sup>1</sup>, Emily Thompson<sup>1</sup>

<sup>1</sup>Carolina Attention Specialists

### **S24. Undetected PTSD in a Clinical Population of Adults With ADHD**

Emilia Sherifi\*<sup>1</sup>, Kathryn Fotinos<sup>1</sup>, Sachintha Lokuge<sup>1</sup>, Zahra Khan<sup>1</sup>, Sarah Drury<sup>1</sup>, Tia Sternat<sup>1</sup>, Irvin Epstein<sup>1</sup>, Catherine Cameron<sup>1</sup>, Isaac Szpindel<sup>1</sup>, Martin Katzman<sup>1</sup>

<sup>1</sup>START Clinic for Mood and Anxiety Disorders

### **S25. Self-Perceived Character Strengths of Youth With ADHD**

Francesca Trane\*<sup>1</sup>, Masha R. Jones<sup>1</sup>, Osman Umarji<sup>1</sup>, Susanne M. Jaeggi<sup>1</sup>

<sup>1</sup>University of California

### **S26. Outcomes of Nonmedical Use of ADHD Stimulants: Results of a Comprehensive Review**

Stephen Faraone\*<sup>1</sup>, Anthony Rostain<sup>2</sup>, C. Brendan Montano<sup>3</sup>, Oren Mason<sup>4</sup>, Kevin Antshel<sup>5</sup>, Jeffrey Newcorn<sup>6</sup>

<sup>1</sup>SUNY Upstate Medical University, <sup>2</sup>University of Pennsylvania, Perelman School of Medicine <sup>3</sup>Connecticut Clinical Research, <sup>4</sup>Attention MD, <sup>5</sup>Syracuse University, <sup>6</sup>Icahn School of Medicine at Mount Sinai

### **★ S27. Motivations and Behaviors of Non-Medical Use of Attention Deficit Hyperactivity Disorder (ADHD) Medications Among Adults**

Stephen Faraone\*<sup>1</sup>, Anthony Rostain<sup>2</sup>, Jeffrey Newcorn<sup>3</sup>

<sup>1</sup>SUNY Upstate Medical University, <sup>2</sup>University of Pennsylvania, Perelman School of Medicine, <sup>3</sup>Mount Sinai Medical Center

### **S28. Expectancies for the Effects of Stimulant Medication by Adolescents in Pediatric Primary Care Treatment for ADHD**

Brooke Molina\*<sup>1</sup>, Rachel Lindstrom<sup>2</sup>, Heidi Kipp<sup>2</sup>, Heather Joseph<sup>3</sup>, Frances Wang<sup>2</sup>, David Kolko<sup>1</sup>, Geetha Subramaniam<sup>4</sup>, David Liu<sup>4</sup>, Sarah Pedersen<sup>1</sup>

<sup>1</sup>University of Pittsburgh, <sup>2</sup>University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, <sup>3</sup>University of Pittsburgh School of Medicine, <sup>4</sup>National Institute on Drug Abuse

### **★ Data Blitz**

## POSTERS

★ **S29. The Association Between Maternal Antiepileptic Drug Use During Pregnancy and Offspring ADHD**

Kelsey Wiggs\*<sup>1</sup>, Martin Rickert<sup>1</sup>, Ayesha Sujan<sup>1</sup>, Patrick Quinn<sup>1</sup>, Paul Lichtenstein<sup>2</sup>, Henrik Larsson<sup>3</sup>, Sara Oberg<sup>4</sup>, Brian D'Onofrio<sup>5</sup>

<sup>1</sup>Indiana University, <sup>2</sup>Karolinska Institute, <sup>3</sup>Karolinska Institute and Örebro University, <sup>4</sup>Karolinska Institute and Harvard University, <sup>5</sup>Indiana University and Karolinska Institute

**S30. Temporal Reward Discounting in College Students With ADHD**

Anouk Scheres<sup>1</sup>, Mary Solanto\*<sup>2</sup>

<sup>1</sup>Radboud University, <sup>2</sup>Hofstra-Northwell School of Medicine

**S31. TMS-Evoked Motor Cortex Inhibition and Modulation: Relationship to ADHD Symptom Severity and Response Inhibition in Children**

Stewart Mostofsky\*<sup>1</sup>, Donald Gilbert<sup>2</sup>, Steve Wu<sup>2</sup>, Ernest Pedapati<sup>2</sup>, Kathryn Hirabayshi<sup>3</sup>, Deana Crocetti<sup>3</sup>, Paul Horn<sup>2</sup>, Eric Wasserman<sup>4</sup>

<sup>1</sup>Center for Neurodevelopmental and Imaging Research, <sup>2</sup>Cincinnati Children's Hospital Medical Center, <sup>3</sup>CNIR, Kennedy Krieger Institute, <sup>4</sup>National Institutes of Health

**S32. Sensitivity to Reward and Punishment in Children With ADHD: The Impact of Comorbid Internalizing Disorders and Sex**

Keri Rosch\*<sup>1</sup>, Stewart Mostofsky<sup>2</sup>, Craig Colder<sup>3</sup>, Karen Seymour<sup>4</sup>

<sup>1</sup>Kennedy Krieger Institute/Johns Hopkins, <sup>2</sup>Center for Neurodevelopmental and Imaging Research, <sup>3</sup>University at Buffalo, <sup>4</sup>Johns Hopkins University School of Medicine

★ **S33. Prevalence and Correlates of Attention-Deficit/Hyperactivity Disorder Among Youth With 16p11.2 Copy Number Variation**

Amandeep Jutla\*<sup>1</sup>

<sup>1</sup>Columbia University and New York State Psychiatric Institute

**S34. Mirror Overflow Movements in ADHD Due to Physiological Immaturity of the Motor System**

John Adamek\*<sup>1</sup>, Danielle McAuliffe<sup>1</sup>, Stewart Mostofsky<sup>1</sup>, Joshua Ewen<sup>1</sup>

<sup>1</sup>Kennedy Krieger Institute



## POSTERS

★ **S35. A Pilot MRI Study of Brain-Based Iron Concentrations' Relation to Attention and Cognitive Control**

Alison Pritchard<sup>\*1</sup>, Xu Li<sup>1</sup>, Matthew Ryan<sup>1</sup>, Elizabeth Offermann<sup>1</sup>, Corina Zisman<sup>1</sup>, Lin Chen<sup>1</sup>, Natalie Ridgely<sup>1</sup>, Alec Sweatman<sup>1</sup>, E. Mark Mahone<sup>1</sup>  
<sup>1</sup>Kennedy Krieger Institute

**S36. Dasotraline in Children With Attention Deficit Hyperactivity Disorder: Effects on Insomnia and Sleep Habits**

Robert Goldman<sup>\*1</sup>, Seth Hopkins<sup>1</sup>, Kenneth Koblan<sup>1</sup>, Andrei Pikalov<sup>1</sup>, Matthew Mandel<sup>1</sup>, Jay Hsu<sup>1</sup>, Antony Loebel<sup>1</sup>  
<sup>1</sup>Sunovion Pharmaceuticals, Inc.

## NOTES

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

# AUTHOR INDEX

Aaronson, Benjamin	60	Chowdhry, Fatima	58
Able, Richard	52	Chronis-Tuscano, Andrea	59
Adamek, John	62	Clark, Dav	53
Adewole, Toyin	58	Coffey, Barbara	39, 47
Adjei, Akwete	57	Coghill, David	11, 29
Adler, Amos	59	Colder, Craig	62
Adler, Lenard	19, 39, 52, 56	Collado, Elias	55
Ahmann, Elizabeth	54	Connor, Carol	60
Albert, Avery	53, 54	Corbeil, Thomas	60
Anastopoulos, Arthur	53	Cortese, Samuele	51
Antshel, Kevin	53, 54, 61	Crocetti, Deana	62
Arnett, Anne	9	Cutler, Andrew J.	51, 52, 58
Arnold, L. Eugene	45	Davis, Naomi	54
Arnsten, Amy	12, 33	Day, Stephanie	60
Asherson, Philip	44	DeLoss, Denton	51, 52
Baker, Ross	57	DeLuca, John	59
Barkley, Russell	36	Denckla, Martha Bridge	7, 34
Barrett, Andrew	52, 58	DeSousa, Norberto	52, 57
Baum, Rebecca	53	Di Martino, Adriana	17, 44
Becker, Julianna	55, 60	DiSalvo, Maura	56, 59
Benjamin, Abigail	59	Dobryakova, Ekaterina	59
Bernanke, Joel	60	D'Onofrio, Brian	62
Biederman, Itai	52, 59	Dougherty, Donald	37
Biederman, Joseph	8, 19, 34, 48, 52, 56,	Drury, Sarah	55, 61
	59	Duarte, Cristiane	60
Blader, Joseph	39, 53	Eddy, Laura	9, 53
Boland, Heidi	56	Engelking, Dorothy	57
Bolotin, Hannah	60	Epstein, Irvin	55, 61
Boucicaut, Laurie	53	Epstein, Jeffrey	51, 53
Bower, Jeffrey D.	51	Estes, Annette	60
Braeckman, Rene	35, 52, 58	Ewen, Joshua	62
Bressolle, Francoise	58	Fageera, Weam	9, 56
Brinkman, William	53	Faraone, Stephen V.	8, 15, 35, 43, 51, 52,
Brown, Lawrence	19		54, 56, 57, 59, 60, 61
Brown, Thomas	19, 51	Findlin, Robert	53
Brugman, R. Derek	61	Fitzgerald, Maura	52
Bruton, Alisha	56	Fogleman, Nicholas	9
Busch, Betsy	19	Fotinos, Kathryn	55, 61
Cameron, Catherine	55, 61	Franke, Barbara	54
Cañadas, Elena	51, 52	Freshwater, Ed	57
Ceresoli-Borroni, Gianpiera	58	Fried, Ronna	52, 59
Chaudhary, Inder	57	Froehlich, Tanya	19, 53
Chaumette, Boris	56	Fuemmeler, Bernard	55
Chen, David	53	Gardner, William	53
Chen, Jie	51, 52	Gellar, Daniel	39, 47
Chen, Lin	63	Gilbert, Donald	62
Chen, Qi	60	Glaser, Amy	53
Childress, Ann	19, 52	Glatt, Stephen	56

# AUTHOR INDEX

Gluck, Mark	59	Koblan, Kenneth	63
Gnagy, Elizabeth	54	Koch, Carolyn	59
Goldman, Robert	63	Kolko, David	61
Gomeni, Roberto	58	Kollins, Scott	19, 51, 52, 54, 55, 57, 60
Gonzalez-Heydrich, Joseph	47	Komolova, Marina	51
Goodman, David	20	Kooij, J.J. Sandra	33
Gray, Kevin	38	Krone, Beth	20, 56
Grizenko, Natalie	56	Kupper, Robert J.	57
Guenther, Sven	52, 58	Laage, Thomas	57
Halperin, Jeffrey	55	Ladouceur, Cecile	54
Hart, Alison	57	Langberg, Joshua	53
Hashimoto, Kimi	55	Lanier, Jane	59
Heiligenstein, John	20	Larsson, Henrik	60, 62
Helminen, Emily	54	Leoni, Matthew	57
Herman, Barry	51, 58	Levin, Frances	19, 37
Hernandez, Mariely	55	Li, Xu	63
Herzallah, Mohammad	59	Lichtenstein, Paul	62
Hess, Jonathan	9, 56	Lichtenstein, Phil	53
Hidalgo, Geneva	55	Lighthall, Rachel	54
Hirabayshi, Kathryn	62	Lindstrom, Rachel	54, 61
Hobart, Mary	57	Liranso, Tesfaye	58
Hoogman, Martine	54	Liu, David	61
Hopkins, Seth	63	Loebel, Antony	63
Horn, Paul	62	Lokuge, Sachintha	55, 61
Hoyo, Cathrine	55	Luna, Alex	60
Hsu, Jay	63	Lunsford-Avery, Jessica	54, 60
Inclledon, Bev	52, 57	Lusby, Cara	60
Jacobson, Lisa	55	Lutz, Jacqueline	52
Jaeggi, Susanne M.	61	Lynn, Noelle	55
Jayanthi, Ramya	55	Madera, Jessica	57
Jones, Erin	55	Mahbubhani, Shelagh	55
Jones, Masha R.	60, 61	Mahone, E. Mark	63
Jones, Neil	54	Mandel, Matthew	63
Joober, Ridha	56	Manor, Iris	46
Joseph, Heather	61	Marraffino, Andrea	51, 52, 57
Jutla, Amandeep	35, 62	Mason, Oren	61
Kafantaris, Vivian	53	Mattingly, Greg	20
Kamimura-Nishimura, Kelly	53	McAuliffe, Danielle	62
Kando, Judith	51, 58	McBurnett, Keith	20, 39
Katzman, Martin	19, 55, 61	McCafferty, Debra	59
Kean, James	35, 58	McClelland, Jesse	55
Kelberman, Caroline	59	McCloud, Will	60
Kelleher, Kelly	53	McQuade, Robert	57
Kennedy, James	16, 43	Meinzer, Michael	59
Khan, Zahra	55, 61	Melmed, Raun	52
King, Thomas	51, 58	Merikangas, Kathleen	14, 33, 48
Kipp, Heidi	61	Mickle, Travis	52, 58
Knouse, Laura	36		

# AUTHOR INDEX

Mitchell, John	54, 60	Sallee, Randy	52, 57
Mlodnicka, Agnieszka	9	Sarkis, Elias	52
Molina, Brooke	20, 39, 54, 61	Sasser, Tyler	60
Montano, C. Brendan	61	Saviet, Micah	54
Mostofsky, Stewart	53, 59, 62	Schachar, Russell	19, 43
Motee, Al-Ashhab	59	Schechter, Julia	55
Munson, Jeffrey	60	Scheres, Anouk	62
Murphy, Susan	55	Scherrer, Sarah	55
Mustafa, Mousa	59	Schulz, Kurt	56
Nasser, Azmi	58	Sengupta, Sarojini M.	56
Natsheh, Joman	59	Setnik, Beatrice	58
Newcom, Jeffrey	19, 29, 56, 57, 61	Seymour, Karen	19, 59, 62
Nierenberg, Andrew	20	Shaw, Philip	18, 44
Nigg, Joel	13, 33	Sherifi, Emilia	55, 61
Noyes, Elizabeth	52, 59	Shiflett, Michael	59
Oberg, Sara	62	Sikes, Carolyn	57
Oddo, Lauren	59	Silvia, Paul	53
Offermann, Elizabeth	63	Simmons, Jessica	53, 54
O'Neill, Sarah	55	Sloan, Jessica	60
Padilla, Americo	57	Smith, Adam	52
Pardo, Antonio	51, 58	Smith, Logan	55, 60
Patak, Jameson	56	Solanto, Mary	20, 39, 62
Pedapati, Ernest	62	Sonuga-Barke, Edmund	10, 29, 45
Pedersen, Sarah	61	Soutullo, César	48
Pelham, William	54	Spencer, Thomas J.	8
Peugh, James	53	Stein, Mark	19, 60
Pfiffner, Linda	36	Sternat, Tia	55, 61
Pikalov, Andrei	63	Stevenson, Amy	61
Pliszka, Steven	19, 35, 45, 47, 53, 57	Subramaniam, Geetha	61
Po, Michelle	51	Sujan, Ayesha	62
Posner, Jonathan	19, 45, 60	Surman, Craig	20, 46, 56
Potter, Joshua	55	Sweatman, Alec	63
Pritchard, Alison	35, 55, 63	Sweitzer, Maggie	54, 60
Quinn, Patrick	62	Szpindel, Isaac	55, 61
Rajendran, Khushmand	55	Tate, Michael	9
Ramsay, J. Russell	46	Taylor, Lea	9, 53, 54
Rhodewal, Lauren	56	Teuscher, Nathan	57
Rickert, Martin	62	Thompson, Emily	61
Ridgely, Natalie	55, 63	Trane, Francesca	60, 61
Riesenberg, Rob	57	Uchida, Mai	8
Robertson, Brigitte	51, 52	Umarji, Osman	60, 61
Robinson, Joshua	59	Vasko, John	59
Rohde, Luis	19	Vaudreuil, Carrie	56
Rosch, Keri	59, 62	Versace, Amelia	54
Rostain, Anthony	20, 61	Volosov, Andrew	57
Roupe, Kathryn	52	Waite, Roberta	20
Roy, Perry	61	Wang, Frances	61
Ryan, Matthew	63	Wasserman, Eric	62

## AUTHOR INDEX

Webster, Lynn	58	Wu, Steve	62
Weiss, Margaret	20	Xu, Jiahong	58
Wigal, Sharon	35, 57	Yule, Amy	37
Wigal, Timothy	57	Zabel, T. Andrew	55
Wiggs, Kelsey	9, 36, 62	Zamora, Cynthia	52
Wilens, Timothy	37, 39, 57	Zargar, Elham	60
Wilson, Tracey	54	Zhang, Wei	52
Winkler, Aaron	60	Zhang-James, Yanli	36, 54, 60
Woodworth, Yvonne	52, 59	Zisman, Corina	55, 63
Wozniak, Janet	48	Zucker, Nancy	55

## NOTES

[illegible]

## NOTES

[illegible]





**Become an APSARD Member Today!**

**Visit [www.APSARD.org](http://www.APSARD.org) for details!**

